Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
25,700 | 2018-01-31 00:00:00 UTC | Anthem (ANTM) Tops Q4 Earnings & Revenues, Issues '18 View | ABBV | https://www.nasdaq.com/articles/anthem-antm-tops-q4-earnings-revenues-issues-18-view-2018-01-31 | null | null | Anthem Inc.'sANTM fourth-quarter 2017 adjusted net income per share of $1.29 surpassed the Zacks Consensus Estimate of $1.25 by 3.2%. The bottom line, however declined 27% year over year.
For 2017, the company's adjusted net income came at $12.04 per share, up 9.5% from the last year.
Operating revenues of $22.4 billio... | Among other players in the Medical sector that have reported their fourth-quarter earnings so far, AbbVie Inc. ABBV , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Rep... | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Anthem, Inc. (ANTM): Free Stock Analysis Report To read this article on Zacks.com click here. Among other players in the Me... | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Anthem, Inc. (ANTM): Free Stock Analysis Report To read this article on Zacks.com click here. Among other players in the Me... | Among other players in the Medical sector that have reported their fourth-quarter earnings so far, AbbVie Inc. ABBV , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Rep... |
25,701 | 2018-01-31 00:00:00 UTC | The Best Arthritis Drug/Treatment Stocks on the Market Right Now | ABBV | https://www.nasdaq.com/articles/best-arthritis-drugtreatment-stocks-market-right-now-2018-01-31 | null | null | Around 350 million people across the world suffer from arthritis, with over 54 million Americans in that group. Treating arthritis costs at least $81 billion each year. It's not surprising that three of the five top-selling drugs in the world in 2017 treated at least one type of arthritis.
But the enormous market for a... | Still, though, AbbVie CEO Rick Gonzalez stated at a recent conference that the company expects "manageable erosion" in sales for Humira and that the drug will continue to generate significant cash flow through 2025 and beyond. 1: AbbVie AbbVie claims the best-selling drug in the world with Humira. Humira generated a wh... | 2: Celgene Celgene is the only big biopharmaceutical company to enjoy faster revenue growth than AbbVie in recent years. 1: AbbVie AbbVie claims the best-selling drug in the world with Humira. Humira generated a whopping $18.4 billion in 2017, around 65% of AbbVie's total revenue last year. | Other solid picks I definitely like AbbVie and Celgene as the best arthritis drug/treatment stocks on the market. 1: AbbVie AbbVie claims the best-selling drug in the world with Humira. Humira generated a whopping $18.4 billion in 2017, around 65% of AbbVie's total revenue last year. | I view AbbVie as the best big pharma stock on the market . Other solid picks I definitely like AbbVie and Celgene as the best arthritis drug/treatment stocks on the market. 1: AbbVie AbbVie claims the best-selling drug in the world with Humira. |
25,702 | 2018-01-30 00:00:00 UTC | 3 Big Biotech Stocks With Major Catalysts on the Way | ABBV | https://www.nasdaq.com/articles/3-big-biotech-stocks-major-catalysts-way-2018-01-30 | null | null | Once a company grows to the size of AbbVie Inc. (NYSE: ABBV) , Celgene Corporation (NASDAQ: CELG) , or Gilead Sciences, Inc. (NASDAQ: GILD) , moving the needle forward gets a lot harder. That doesn't stop their management teams from trying, though.
Despite their immense size, each of these biotech stocks could make big... | While we're waiting for the FDA's approval decision concerning endometriosis pain, AbbVie and Neurocrine are expected to report results for a late-stage study designed to expand Elagolix to treat heavy menstrual bleeding associated with non-cancerous growths in the uterus. Once a company grows to the size of AbbVie Inc... | While we're waiting for the FDA's approval decision concerning endometriosis pain, AbbVie and Neurocrine are expected to report results for a late-stage study designed to expand Elagolix to treat heavy menstrual bleeding associated with non-cancerous growths in the uterus. Unfortunately, for Gilead Sciences, competitio... | Unfortunately, for Gilead Sciences, competition from the likes of AbbVie has hammered annual sales of its hepatitis C treatments from a peak of $19.1 billion in 2015 to a range expected to fall between $8.5 billion and $9 billion when the company reports 2017 results on Feb. 6. Once a company grows to the size of AbbVi... | Unfortunately, for Gilead Sciences, competition from the likes of AbbVie has hammered annual sales of its hepatitis C treatments from a peak of $19.1 billion in 2015 to a range expected to fall between $8.5 billion and $9 billion when the company reports 2017 results on Feb. 6. Once a company grows to the size of AbbVi... |
25,703 | 2018-01-30 00:00:00 UTC | Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX | ABBV | https://www.nasdaq.com/articles/drug-biotech-stocks-q4-earnings-due-on-jan-31%3A-lly-vrtx-2018-01-30 | null | null | The fourth-quarter 2017 earnings season is in full swing with financial figures from 133 S&P 500 members or 26% of the index already out as of Jan 26, 2018 per the latest Earnings Preview .
Total earnings for these index members jumped 12.3% from the year-ago quarter, driven by 8.8% improvement in revenues. The beat ra... | The pharma bigwigs having reported last week are Novartis NVS and AbbVie ABBV , which surpassed both earnings and sales estimates in the quarter under review. While Novartis raised its sales guidance for 2018, AbbVie increased its previously issued earnings expectations for the year. Click to get this free report Eli L... | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Celgene Corporatio... | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Celgene Corporatio... | The pharma bigwigs having reported last week are Novartis NVS and AbbVie ABBV , which surpassed both earnings and sales estimates in the quarter under review. While Novartis raised its sales guidance for 2018, AbbVie increased its previously issued earnings expectations for the year. Click to get this free report Eli L... |
25,704 | 2018-01-29 00:00:00 UTC | 3 Things Driving AbbVie Inc. Stock After Q4 Earnings Report | ABBV | https://www.nasdaq.com/articles/3-things-driving-abbvie-inc-stock-after-q4-earnings-report-2018-01-29 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie Inc. (NYSE: ABBV ) reported fourth-quarter- and full-year-earnings Friday morning, and ABBV stock stock responded by jumping more than 10% in early trading. What did the pharmaceuticals giant do right? There are three things that stood out.
Top-and B... | And with good reason: with $4.89 billion in sales, Humira accounted for more than half of AbbVie's total fourth-quarter sales-a 14% improvement over the same quarter a year ago. While several products, including AndroGel and Duodopa, saw decreased revenues, ABBV had 10 drugs that topped $100 million in sales in the fou... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc. (NYSE: ABBV ) reported fourth-quarter- and full-year-earnings Friday morning, and ABBV stock stock responded by jumping more than 10% in early trading. Top-and Bottom-Line Beats ABBV stock beat consensus fourth-quarter estimates on earnings and ... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc. (NYSE: ABBV ) reported fourth-quarter- and full-year-earnings Friday morning, and ABBV stock stock responded by jumping more than 10% in early trading. 5 Energy Stocks Coming Back From the Dead Strong Non-Humira Growth for ABBV Stock AbbVie has ... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc. (NYSE: ABBV ) reported fourth-quarter- and full-year-earnings Friday morning, and ABBV stock stock responded by jumping more than 10% in early trading. More from InvestorPlace These 7 Goldman Sachs Picks Are Top Stocks to Buy for 2018 7 Stocks S... |
25,705 | 2018-01-29 00:00:00 UTC | AstraZeneca's Triple Combo COPD Inhaler Positive in Phase III | ABBV | https://www.nasdaq.com/articles/astrazenecas-triple-combo-copd-inhaler-positive-in-phase-iii-2018-01-29 | null | null | AstraZeneca PlcAZN announced positive top-line results from a phase III study evaluating its investigational triple combination therapy PT010 for the treatment of chronic obstructive pulmonary disease (COPD).
PT010 is a combination of budesonide, an ICS with glycopyrronium, a long-acting muscarinic antagonist (LAMA) an... | A better-ranked stock from the health care space is AbbVie Inc. ABBV carrying a Zacks Rank #2 (Buy). AbbVie's earnings per share estimates have moved up from $6.55 to $6.58 for 2018 in the last 60 days. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock... | Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Innoviva, Inc. (INVA): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock from the health care ... | Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Innoviva, Inc. (INVA): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock from the health care ... | A better-ranked stock from the health care space is AbbVie Inc. ABBV carrying a Zacks Rank #2 (Buy). AbbVie's earnings per share estimates have moved up from $6.55 to $6.58 for 2018 in the last 60 days. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock... |
25,706 | 2018-01-29 00:00:00 UTC | Stock Market News for Jan 29, 2018 | ABBV | https://www.nasdaq.com/articles/stock-market-news-for-jan-29-2018-2018-01-29 | null | null | All the three key U.S. indexes closed at record levels on Friday following better-than-expected earnings from Intel, AbbVie and Honeywell. Additionally, continued economic growth and optimism over a weaker dollar had a positive impact on investor sentiment. The S&P 500 has finished at a record level for 14 trading days... | ( Read More ) Shares of AbbVie jumped 13.8% after the pharmaceutical products manufacturer reported fourth quarter EPS and revenues, which surpassed the respective Zacks Consensus Estimate. All the three key U.S. indexes closed at record levels on Friday following better-than-expected earnings from Intel, AbbVie and Ho... | Upbeat Q4 Earnings Boost Sentiment Encouraging earnings results from Intel Corporation INTC , AbbVie Inc. ABBV and Honeywell International Inc HON lent further impetus to the markets' rally. Click to get this free report Netflix, Inc. (NFLX): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Dia... | ( Read More ) Shares of AbbVie jumped 13.8% after the pharmaceutical products manufacturer reported fourth quarter EPS and revenues, which surpassed the respective Zacks Consensus Estimate. Click to get this free report Netflix, Inc. (NFLX): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Diag... | All the three key U.S. indexes closed at record levels on Friday following better-than-expected earnings from Intel, AbbVie and Honeywell. Upbeat Q4 Earnings Boost Sentiment Encouraging earnings results from Intel Corporation INTC , AbbVie Inc. ABBV and Honeywell International Inc HON lent further impetus to the market... |
25,707 | 2018-01-29 00:00:00 UTC | What to Expect in Pfizer's Q4 Earnings Results | ABBV | https://www.nasdaq.com/articles/what-expect-pfizers-q4-earnings-results-2018-01-29 | null | null | While the stock market roared in 2017, Pfizer (NYSE: PFE) turned in a respectable, but not spectacular, performance, with its stock gaining 11.5%. The big pharma company's third-quarter results, announced in October , highlighted why -- slow operational sales growth but solid earnings increases.
Pfizer provides an upda... | AbbVie just bumped up its 2018 earnings outlook as a result of the impact of tax reform. *Stock Advisor returns as of January 2, 2018 Keith Speights owns shares of AbbVie and Pfizer. The big pharma company's third-quarter results, announced in October , highlighted why -- slow operational sales growth but solid earning... | AbbVie just bumped up its 2018 earnings outlook as a result of the impact of tax reform. *Stock Advisor returns as of January 2, 2018 Keith Speights owns shares of AbbVie and Pfizer. The big pharma company's third-quarter results, announced in October , highlighted why -- slow operational sales growth but solid earning... | AbbVie just bumped up its 2018 earnings outlook as a result of the impact of tax reform. *Stock Advisor returns as of January 2, 2018 Keith Speights owns shares of AbbVie and Pfizer. Positives There's no reason to think that Pfizer's fast-growing drugs didn't keep their solid momentum going during the fourth quarter. | AbbVie just bumped up its 2018 earnings outlook as a result of the impact of tax reform. *Stock Advisor returns as of January 2, 2018 Keith Speights owns shares of AbbVie and Pfizer. Here's what to expect in Pfizer's Q4 earnings results. |
25,708 | 2018-01-29 00:00:00 UTC | AbbVie (ABBV) Soars on Q4 Results: Key Takeaways from the Earnings Call | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-soars-q4-results-key-takeaways-earnings-call-2018-01-29 | null | null | AbbVie's ABBV shares jumped 13.8% following the release of better-than-expected fourth quarter 2017 results and an upbeat outlook for 2018. Results were driven by the performance of Humira, Imbruvica and Mavyret. Imbruvica continued to witness strong uptake for the chronic lymphocytic leukemia ("CLL") indication while ... | AbbVie's ABBV shares jumped 13.8% following the release of better-than-expected fourth quarter 2017 results and an upbeat outlook for 2018. AbbVie expects 2018 earnings per share in the range of $7.33 - $7.43 on revenues of almost $32 billion. Cash Repatriation/Capital Deployment: The U.S. tax reform will allow AbbVie ... | In addition to working on expanding the label of approved products like Imbruvica and Venclexta, AbbVie's late-stage pipeline includes candidates like upadacitinib (rheumatoid arthritis - RA, Crohn's disease) and risankizumab (psoriasis, Crohn's disease). Click to get this free report Pfizer, Inc. (PFE): Free Stock Ana... | AbbVie is a Zacks Rank #2 (Buy) stock - you can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report AbbVie Inc. (A... | AbbVie expects 2018 earnings per share in the range of $7.33 - $7.43 on revenues of almost $32 billion. AbbVie's ABBV shares jumped 13.8% following the release of better-than-expected fourth quarter 2017 results and an upbeat outlook for 2018. Cash Repatriation/Capital Deployment: The U.S. tax reform will allow AbbVie ... |
25,709 | 2018-01-29 00:00:00 UTC | Strength Seen in AbbVie (ABBV): Stock Soars 13.8% | ABBV | https://www.nasdaq.com/articles/strength-seen-in-abbvie-abbv%3A-stock-soars-13.8-2018-01-29 | null | null | AbbVie Inc.ABBV was a big mover last session, as the company saw its shares nearly 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company-as the stock is now up 26% in the past one-month time frame.
The move came ... | AbbVie Inc.ABBV was a big mover last session, as the company saw its shares nearly 14% on the day. AbbVie currently has a Zacks Rank #2 (Buy) while its Earnings ESP is positive. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Investors interested in the Large Cap Pharmaceuticals industry may consider H. Lundbec... | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Investors interested in the Large Cap Pharmaceuticals industry may consider H. Lundbeck A/S HLUYY , which has a Zacks Rank #1 (Strong Buy). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Rep... | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Investors interested in the Large Cap Pharmaceuticals industry may consider H. Lundbeck A/S HLUYY , which has a Zacks Rank #1 (Strong Buy). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Rep... | AbbVie currently has a Zacks Rank #2 (Buy) while its Earnings ESP is positive. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Investors interested in the Large Cap Pharmaceuticals industry may consider H. Lundbeck A/S HLUYY , which has a Zacks Rank #1 (Strong Buy). AbbVie Inc.ABBV was a big mover last session,... |
25,710 | 2018-01-29 00:00:00 UTC | Notable ETF Inflow Detected - MTUM, BA, C, ABBV | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-mtum-ba-c-abbv-2018-01-29 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $255.6 million dollar inflow -- that's a 3.6% increase week over week in outstanding units (fr... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is down about 0.3%, Citigroup Inc (Symbol: C) is up about 0.6%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , o... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is down about 0.3%, Citigroup Inc (Symbol: C) is up about 0.6%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.6%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price perform... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is down about 0.3%, Citigroup Inc (Symbol: C) is up about 0.6%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , o... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is down about 0.3%, Citigroup Inc (Symbol: C) is up about 0.6%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , o... |
25,711 | 2018-01-29 00:00:00 UTC | Roche Hemophilia Drug Hemlibra Gets Positive CHMP Opinion | ABBV | https://www.nasdaq.com/articles/roche-hemophilia-drug-hemlibra-gets-positive-chmp-opinion-2018-01-29 | null | null | RocheRHHBY announced that the EU Committee for Medicinal Products for Human Use ("CHMP") has adopted a positive opinion for Hemlibra (emicizumab) for routine prophylaxis of bleeding episodes in patients suffering from hemophilia A with factor VIII inhibitors.
The CHMP has recommended the drug for use in all age groups.... | We note that Roche is developing Venclexta in collaboration with AbbVie ABBV . AbbVie is commercializing the drug outside the United States. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amg... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Roche is developing Venclexta in collab... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Roche is developing Venclexta in collab... | We note that Roche is developing Venclexta in collaboration with AbbVie ABBV . AbbVie is commercializing the drug outside the United States. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amg... |
25,712 | 2018-01-28 00:00:00 UTC | Why Dividend Investors Want to Own AbbVie in 2018 | ABBV | https://www.nasdaq.com/articles/why-dividend-investors-want-own-abbvie-2018-2018-01-28 | null | null | Looking for a stock that offers an above average dividend fueled by double-digit profit growth year after successful year?
AbbVie, Inc. (NYSE: ABBV) has already ticked those boxes and looks set to do it again. Dividend investors who have been kicking themselves for avoiding the stock's debut might want to take another ... | AbbVie's dividend offers an above-average 2.4% yield at the moment, plus management just laid out some big reasons investors can look forward to rapid profit growth in 2018 and sustainable gains in the years ahead. AbbVie paid $5.8 billion upfront to get its hands on the cancer drug candidate, but early survival data f... | Trial results, potential new drug launches, and label expansions have set AbbVie up for growth in the years ahead. AbbVie, Inc. (NYSE: ABBV) has already ticked those boxes and looks set to do it again. AbbVie's dividend offers an above-average 2.4% yield at the moment, plus management just laid out some big reasons inv... | AbbVie's dividend offers an above-average 2.4% yield at the moment, plus management just laid out some big reasons investors can look forward to rapid profit growth in 2018 and sustainable gains in the years ahead. Trial results, potential new drug launches, and label expansions have set AbbVie up for growth in the yea... | Trial results, potential new drug launches, and label expansions have set AbbVie up for growth in the years ahead. AbbVie, Inc. (NYSE: ABBV) has already ticked those boxes and looks set to do it again. AbbVie's dividend offers an above-average 2.4% yield at the moment, plus management just laid out some big reasons inv... |
25,713 | 2018-01-26 00:00:00 UTC | Novartis Gets Spark Therapeutics' Luxterna License Outside US | ABBV | https://www.nasdaq.com/articles/novartis-gets-spark-therapeutics-luxterna-license-outside-us-2018-01-26 | null | null | Novartis AGNVS entered into a licensing agreement with Spark Therapeutics to develop, register and commercialize Luxturna (voretigene neparvovec) in markets outside the United States.
We note Luxturna was approved in the United States on Dec 19, 2017 as one-time gene therapy to restore functional vision in children and... | The proposed biosimilar version of AbbVie. Inc.'s ABBV Humira (adalimumab) has also been accepted for review by the FDA. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The proposed biosimilar version of AbbVie. Inc.'s AB... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The proposed biosimilar version of AbbVie. Inc.'s AB... | The proposed biosimilar version of AbbVie. Inc.'s ABBV Humira (adalimumab) has also been accepted for review by the FDA. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free... |
25,714 | 2018-01-26 00:00:00 UTC | US Stocks Extend Gains as Health Care, Tech Sectors Edge Higher | ABBV | https://www.nasdaq.com/articles/us-stocks-extend-gains-health-care-tech-sectors-edge-higher-2018-01-26 | null | null | US equity benchmarks were extending gains on Friday afternoon despite a lower-than-expected estimate of fourth quarter economic growth as gains in the health care, technology and energy sectors helped to offset declines among utilities and real estate stocks.
The economy grew by an estimated 2.6% on an annualized basis... | Hot on its heels was pharmaceutical company Abbvie ( ABBV ), up by 9.4% after reporting a fourth quarter adjusted net profit and revenue which beat analysts' estimates. In equities, gainers on the Standard & Poor's 500 Index were led by Intel ( INTC ), 9.5% higher after the technology company posted better-than-expecte... | Hot on its heels was pharmaceutical company Abbvie ( ABBV ), up by 9.4% after reporting a fourth quarter adjusted net profit and revenue which beat analysts' estimates. US equity benchmarks were extending gains on Friday afternoon despite a lower-than-expected estimate of fourth quarter economic growth as gains in the ... | Hot on its heels was pharmaceutical company Abbvie ( ABBV ), up by 9.4% after reporting a fourth quarter adjusted net profit and revenue which beat analysts' estimates. In equities, gainers on the Standard & Poor's 500 Index were led by Intel ( INTC ), 9.5% higher after the technology company posted better-than-expecte... | Hot on its heels was pharmaceutical company Abbvie ( ABBV ), up by 9.4% after reporting a fourth quarter adjusted net profit and revenue which beat analysts' estimates. The economy grew by an estimated 2.6% on an annualized basis in the final quarter of 2017, down from a 3.2% annualized growth rate in the third quarter... |
25,715 | 2018-01-26 00:00:00 UTC | AbbVie (ABBV) Q4 Earnings Beat, 2018 View Raised, Shares Up | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q4-earnings-beat-2018-view-raised-shares-up-2018-01-26 | null | null | AbbVie Inc. ABBV reported impressive results in the fourth quarter of 2017. The company surpassed earnings and revenue estimates during the period. Importantly, it raised its earnings expectations for 2018. In response, shares climbed almost 6% in pre-market trading .
AbbVie's shares have soared 90.1% in a year's time,... | AbbVie Inc. ABBV reported impressive results in the fourth quarter of 2017. AbbVie's shares have soared 90.1% in a year's time, significantly outperforming the industry 's 26.5% rally. AbbVie recorded $123 million (up 38.7%) of international profit sharing with Johnson & Johnson JNJ . | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie carries a Zacks Rank #3 (Hold). Click to get this free report Novo Nordisk A/S (NVO): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (... | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie carries a Zacks Rank #3 (Hold). Click to get this free report Novo Nordisk A/S (NVO): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (... | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie carries a Zacks Rank #3 (Hold). AbbVie Inc. ABBV reported impressive results in the fourth quarter of 2017. AbbVie's shares have soared 90.1% in a year's time, significantly outp... |
25,716 | 2018-01-26 00:00:00 UTC | AbbVie Inc Stock Soars on Strong Q4 Earnings Beat | ABBV | https://www.nasdaq.com/articles/abbvie-inc-stock-soars-strong-q4-earnings-beat-2018-01-26 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie Inc (NYSE: ABBV ) stock was flying high today following the release of its earnings report for the fourth quarter of 2017.
Source: Black Stripe via Wikimedia (Modified)
During the fourth quarter of the year, AbbVie Inc reported earnings per share of ... | Source: Black Stripe via Wikimedia (Modified) During the fourth quarter of the year, AbbVie Inc reported earnings per share of $1.48. It was also good news for ABBV stock by beating out Wall Street's earnings per share estimate of $1.44 for the period. Compare Brokers The post AbbVie Inc Stock Soars on Strong Q4 Earnin... | Source: Black Stripe via Wikimedia (Modified) During the fourth quarter of the year, AbbVie Inc reported earnings per share of $1.48. It was also good news for ABBV stock by beating out Wall Street's earnings per share estimate of $1.44 for the period. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbV... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) stock was flying high today following the release of its earnings report for the fourth quarter of 2017. Revenue of $7.74 billion reported by AbbVie Inc for the fourth quarter of the year was also a boon to ABBV stock. Source: Black... | It was also good news for ABBV stock by beating out Wall Street's earnings per share estimate of $1.44 for the period. Revenue of $7.74 billion reported by AbbVie Inc for the fourth quarter of the year was also a boon to ABBV stock. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV )... |
25,717 | 2018-01-26 00:00:00 UTC | A Spate of Q4 Earnings | ABBV | https://www.nasdaq.com/articles/a-spate-of-q4-earnings-2018-01-26 | null | null | Ahead of the opening bell for the final trading day of this week, new U.S. Gross Domestic Product (GDP) figures were released, and, while not exactly disappointing, came up short of what many analysts had been expecting. The first read for Q4 GDP reached 2.6%, lower than the consensus estimate of 2.9%.
Should this figu... | Biotech company AbbVie ABBV is up 3% in today's pre-market on an earnings beat of $1.48 per share from $1.44 expected, on quarterly sales of $7.7 billion which eked out a positive surprise over the $7.6 billion in the Zacks consensus. For more on ABBV's earnings, click here. Click to get this free report AbbVie Inc. (A... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Rockwell Collins, Inc. (COL): Free Stock Analysis Report Honeywell International Inc. (HON): Free Stock Analysis Report To read this article on Zacks.com click here. Biotech company AbbVie ABBV is up 3% in today's pre-market on an earnings bea... | Biotech company AbbVie ABBV is up 3% in today's pre-market on an earnings beat of $1.48 per share from $1.44 expected, on quarterly sales of $7.7 billion which eked out a positive surprise over the $7.6 billion in the Zacks consensus. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Rockwell... | Biotech company AbbVie ABBV is up 3% in today's pre-market on an earnings beat of $1.48 per share from $1.44 expected, on quarterly sales of $7.7 billion which eked out a positive surprise over the $7.6 billion in the Zacks consensus. For more on ABBV's earnings, click here. Click to get this free report AbbVie Inc. (A... |
25,718 | 2018-01-26 00:00:00 UTC | S&P 500 Movers: CL, ABBV | ABBV | https://www.nasdaq.com/articles/sp-500-movers-cl-abbv-2018-01-26 | null | null | In early trading on Friday, shares of AbbVie ( ABBV ) topped the list of the day's best performing components of the S&P 500 index, trading up 8.2%. Year to date, AbbVie registers a 21.2% gain.
And the worst performing S&P 500 component thus far on the day is Colgate-Palmolive ( CL ), trading down 4.9%. Colgate-Palmoli... | In early trading on Friday, shares of AbbVie ( ABBV ) topped the list of the day's best performing components of the S&P 500 index, trading up 8.2%. VIDEO: S&P 500 Movers: CL, ABBV The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Year ... | VIDEO: S&P 500 Movers: CL, ABBV The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Friday, shares of AbbVie ( ABBV ) topped the list of the day's best performing components of the S&P 500 index, trading up 8.2%. Year ... | In early trading on Friday, shares of AbbVie ( ABBV ) topped the list of the day's best performing components of the S&P 500 index, trading up 8.2%. VIDEO: S&P 500 Movers: CL, ABBV The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Year ... | VIDEO: S&P 500 Movers: CL, ABBV The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Friday, shares of AbbVie ( ABBV ) topped the list of the day's best performing components of the S&P 500 index, trading up 8.2%. Year ... |
25,719 | 2018-01-26 00:00:00 UTC | AbbVie (ABBV) Q4 Earnings & Revenues Beat, Guidance Raised | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q4-earnings-revenues-beat-guidance-raised-2018-01-26 | null | null | North Chicago, IL-based AbbVie Inc. ABBV is best known for its autoimmune disease drug, Humira. AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, acti... | North Chicago, IL-based AbbVie Inc. ABBV is best known for its autoimmune disease drug, Humira. AbbVie's performance has been impressive, with the pharmaceuticals company delivering positive surprises in the three of the past four quarter while recording in-line earnings in the other. AbbVie's flagship product Humira i... | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to... | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to... | We have highlighted some of the key stats from this just-revealed announcement below: Earnings: AbbVie's fourth-quarter earnings came in at $1.48 per share, beating the Zacks Consensus Estimate of $1.44. Revenues: AbbVie posted revenues of $7.7 billion, which marginally beat the Zacks Consensus Estimate of $7.6 billion... |
25,720 | 2018-01-26 00:00:00 UTC | Will J&J (JNJ) Witness Deceleration in 2018 Sales Growth? | ABBV | https://www.nasdaq.com/articles/will-jj-jnj-witness-deceleration-in-2018-sales-growth-2018-01-26 | null | null | Johnson & Johnson'sJNJ fourth-quarter 2017 results were mixed as it beat estimates for earnings while missing the same for sales. J&J announced its fourth-quarter results on Jan 23 before markets opened.
As expected, J&J's sales growth accelerated in the second half of the year backed by higher sales in the Pharmaceuti... | Please note that J&J markets Imbruvica in partnership with AbbVie, Inc. ABBV . Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To ... | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Please note that J&J markets Imbruvi... | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Please note that J&J markets Imbruvi... | Please note that J&J markets Imbruvica in partnership with AbbVie, Inc. ABBV . Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To ... |
25,721 | 2018-01-26 00:00:00 UTC | Morning Movers: AbbVie Jumps on Earnings, Colgate Crushed, Gilead Rising | ABBV | https://www.nasdaq.com/articles/morning-movers-abbvie-jumps-earnings-colgate-crushed-gilead-rising-2018-01-26 | null | null | Stocks are rising this morning despite slower-than-expected U.S. economic growth in the fourth quarter as President Donald Trump touted America as an investment destination.
Getty Images
S&P 500 futures have risen 0.3%, while Dow Jones Industrial futures have advanced 55 points, or 0.2%. Nasdaq Composite futures have g... | - Ben Levisohn Morning Movers StarbucksSBUXfiscal first quarter earningslagged in the past yearsee better times aheadpicks from the recent Barron's Roundtable IntelINTCIntel gained on the newsstock's reaction to security worries AbbVieABBVraised its 2018 earnings guidance Colgate-PalmoliveCLreporting a fourth-quarter p... | - Ben Levisohn Morning Movers StarbucksSBUXfiscal first quarter earningslagged in the past yearsee better times aheadpicks from the recent Barron's Roundtable IntelINTCIntel gained on the newsstock's reaction to security worries AbbVieABBVraised its 2018 earnings guidance Colgate-PalmoliveCLreporting a fourth-quarter p... | - Ben Levisohn Morning Movers StarbucksSBUXfiscal first quarter earningslagged in the past yearsee better times aheadpicks from the recent Barron's Roundtable IntelINTCIntel gained on the newsstock's reaction to security worries AbbVieABBVraised its 2018 earnings guidance Colgate-PalmoliveCLreporting a fourth-quarter p... | - Ben Levisohn Morning Movers StarbucksSBUXfiscal first quarter earningslagged in the past yearsee better times aheadpicks from the recent Barron's Roundtable IntelINTCIntel gained on the newsstock's reaction to security worries AbbVieABBVraised its 2018 earnings guidance Colgate-PalmoliveCLreporting a fourth-quarter p... |
25,722 | 2018-01-26 00:00:00 UTC | Why This Biopharma 'Behemoth' Could Soon Become Acquisitive | ABBV | https://www.nasdaq.com/articles/why-biopharma-behemoth-could-soon-become-acquisitive-2018-01-26 | null | null | AbbVie ( ABBV ) surged to a record high Friday after issuing a beat-and-raise earnings report that included guidance for a 9% tax rate in 2018, prompting one analyst to suggest "yet another industry behemoth" could become acquisitive.
[ibd-display-video id=3107223 width=50 float=left autostart=true] For its fourth quar... | AbbVie ( ABBV ) surged to a record high Friday after issuing a beat-and-raise earnings report that included guidance for a 9% tax rate in 2018, prompting one analyst to suggest "yet another industry behemoth" could become acquisitive. Worldwide sales of AbbVie's hepatitis C drugs Viekira and Mavyret advanced more than ... | [ibd-display-video id=3107223 width=50 float=left autostart=true] For its fourth quarter, AbbVie reported adjusted income of $1.48 per share on $7.74 billion in sales, rising 23% and 14%, respectively. AbbVie ( ABBV ) surged to a record high Friday after issuing a beat-and-raise earnings report that included guidance f... | AbbVie expects its effective tax rate to increase to 13% over the next five years due to increased domestic income and investment, Piper Jaffray analyst Christopher Raymond said in his note to clients. AbbVie ( ABBV ) surged to a record high Friday after issuing a beat-and-raise earnings report that included guidance f... | AbbVie ( ABBV ) surged to a record high Friday after issuing a beat-and-raise earnings report that included guidance for a 9% tax rate in 2018, prompting one analyst to suggest "yet another industry behemoth" could become acquisitive. [ibd-display-video id=3107223 width=50 float=left autostart=true] For its fourth quar... |
25,723 | 2018-01-26 00:00:00 UTC | Don’t Chase AbbVie Inc Stock After Its Huge Earnings Win | ABBV | https://www.nasdaq.com/articles/dont-chase-abbvie-inc-stock-after-its-huge-earnings-win-2018-01-26 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
From a fundamental perspective, it's difficult to find anything wrong with AbbVie Inc (NYSE: ABBV ). Friday morning's fourth-quarter results beat consensus on the top and bottom lines for the fourth straight quarter. The midpoint of updated 2018 guidance im... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips From a fundamental perspective, it's difficult to find anything wrong with AbbVie Inc (NYSE: ABBV ). And yet, AbbVie stock trades at less than 16 times that guidance, even after gaining 9% in early trading Friday. AbbVie's multiple of 16 and its growth of 3... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips From a fundamental perspective, it's difficult to find anything wrong with AbbVie Inc (NYSE: ABBV ). And yet, AbbVie stock trades at less than 16 times that guidance, even after gaining 9% in early trading Friday. AbbVie's multiple of 16 and its growth of 3... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips From a fundamental perspective, it's difficult to find anything wrong with AbbVie Inc (NYSE: ABBV ). ABBV Stock Is Cheap, But Not Cheap Enough AbbVie has a pair of drugs in the pipeline that hopefully will cushion any declines in Humira. More From InvestorP... | To top it off, ABBV stock still yields 2.6%. InvestorPlace - Stock Market News, Stock Advice & Trading Tips From a fundamental perspective, it's difficult to find anything wrong with AbbVie Inc (NYSE: ABBV ). And yet, AbbVie stock trades at less than 16 times that guidance, even after gaining 9% in early trading Friday... |
25,724 | 2018-01-26 00:00:00 UTC | 5 Biotech and Pharmaceutical Stocks Going Bonkers | ABBV | https://www.nasdaq.com/articles/5-biotech-and-pharmaceutical-stocks-going-bonkers-2018-01-26 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
This is a market like the world has never seen. U.S. equities are pushing to new record highs on Friday thanks in large part to a moon-shot trajectory by biotech and pharmaceutical stocks. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) is up ro... | Biotech and Pharmaceutical Stocks to Buy: AbbVie (ABBV) AbbVie Inc (NYSE: ABBV ) shares are moving the most aggressively among the ones presented here, up nearly 14% to cap a 25% gain over the past month. The catalyst was headlines that European regulators approved PFE's diabetes drug Steglatro developed in collaborati... | Biotech and Pharmaceutical Stocks to Buy: AbbVie (ABBV) AbbVie Inc (NYSE: ABBV ) shares are moving the most aggressively among the ones presented here, up nearly 14% to cap a 25% gain over the past month. 10 Top-Rated Vanguard Funds to Buy Now Here are five to biotech and pharmaceutical stocks watch: Biotech and Pharma... | Biotech and Pharmaceutical Stocks to Buy: AbbVie (ABBV) AbbVie Inc (NYSE: ABBV ) shares are moving the most aggressively among the ones presented here, up nearly 14% to cap a 25% gain over the past month. 10 Top-Rated Vanguard Funds to Buy Now Here are five to biotech and pharmaceutical stocks watch: Biotech and Pharma... | Biotech and Pharmaceutical Stocks to Buy: AbbVie (ABBV) AbbVie Inc (NYSE: ABBV ) shares are moving the most aggressively among the ones presented here, up nearly 14% to cap a 25% gain over the past month. 10 Top-Rated Vanguard Funds to Buy Now Here are five to biotech and pharmaceutical stocks watch: Biotech and Pharma... |
25,725 | 2018-01-26 00:00:00 UTC | Stocks With Rising Relative Strength: Novartis | ABBV | https://www.nasdaq.com/articles/stocks-rising-relative-strength-novartis-2018-01-26 | null | null | The Relative Strength ( RS ) Rating for Novartis ( NVS ) headed into a higher percentile Friday, as it got a lift from 70 to 75.
[ibd-display-video id=2881825 width=50 float=left autostart=true] IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's pric... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. The Relative Strength ( RS ) Rating for Novartis ( NVS ) headed into a higher percentile Friday, as it got a lift from 70 to 75. Decades of market research shows that the best stocks tend to have an RS Rating ... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. The Relative Strength ( RS ) Rating for Novartis ( NVS ) headed into a higher percentile Friday, as it got a lift from 70 to 75. Biotech And Pharmaceutical Industry And Stock News Stocks With Rising Relative S... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. The score shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database. Biotech And Pharmaceutical Industry And Stock News Stocks With Rising Relative Strength Rat... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. [ibd-display-video id=2881825 width=50 float=left autostart=true] IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over th... |
25,726 | 2018-01-26 00:00:00 UTC | AstraZeneca Gets Relative Strength Rating Upgrade | ABBV | https://www.nasdaq.com/articles/astrazeneca-gets-relative-strength-rating-upgrade-2018-01-26 | null | null | The Relative Strength ( RS ) Rating for AstraZeneca ( AZN ) entered a higher percentile Friday, as it got a lift from 62 to 75.
[ibd-display-video id=2385970 width=50 float=left autostart=true] IBD's proprietary RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's ... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. The Relative Strength ( RS ) Rating for AstraZeneca ( AZN ) entered a higher percentile Friday, as it got a lift from 62 to 75. History reveals that the stocks that go on to make the biggest gains often have a... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. Biotech And Pharmaceutical Industry And Stock News Stocks With Rising Relative Strength Ratings Why Should You Use IBD's Relative Strength Rating? How Relative Strength Line Can Help You Judge A Stock The view... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. See How IBD Helps You Make More Money In Stocks AstraZeneca is within a buy range after clearing a 35.70 buy point in a consolidation . Biotech And Pharmaceutical Industry And Stock News Stocks With Rising Rel... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. See if AstraZeneca can continue to rebound and clear that threshold. But revenue gains moved higher, from -10% to 9%. |
25,727 | 2018-01-26 00:00:00 UTC | This Is By Far the Most Important Number in AbbVie's Q4 Results | ABBV | https://www.nasdaq.com/articles/far-most-important-number-abbvies-q4-results-2018-01-26 | null | null | After AbbVie (NYSE: ABBV) reported its third-quarter results in October, all the signs pointed to the big biotech enjoying its best year ever in 2017. The company was on a roll.
Investors fully expected that the positive momentum would continue when AbbVie announced its fourth-quarter and full-year 2017 results before ... | Investors fully expected that the positive momentum would continue when AbbVie announced its fourth-quarter and full-year 2017 results before the market opened on Friday. While AbbVie's bottom-line performance appears to have significantly worsened, the big drop stemmed from the one-time impact of around $4.5 billion i... | AbbVie announced adjusted diluted earnings per share (EPS) of $1.48 in the fourth quarter, a year-over-year jump of 23%. However, that was skewed by the big repatriation tax, so AbbVie's adjusted tax rate was 18.9%. Over the next five years, AbbVie expects its adjusted tax rate to be around 13%. | Most important number While AbbVie's fourth-quarter numbers were strong, the most important number announced by the company related to the future rather than the past. However, that was skewed by the big repatriation tax, so AbbVie's adjusted tax rate was 18.9%. AbbVie predicts its 2018 effective tax rate will be aroun... | As usual, Humira generated the lion's share of AbbVie's total revenue, with sales of the autoimmune disease drug totaling nearly $4.9 billion in the fourth quarter. Over the next five years, AbbVie expects its adjusted tax rate to be around 13%. After AbbVie (NYSE: ABBV) reported its third-quarter results in October, a... |
25,728 | 2018-01-26 00:00:00 UTC | Blue-Chip Drug Stock, Dow Jones Name Boasts Big Yield, Hits 13-Year High | ABBV | https://www.nasdaq.com/articles/blue-chip-drug-stock-dow-jones-name-boasts-big-yield-hits-13-year-high-2018-01-26 | null | null | Amid renewed strength in the biotech and drug industry, Pfizer ( PFE ) is surging into multiyear-high territory Friday as volume tracked well above average.
[ibd-display-video id=2382612 width=50 float=left autostart=true] The blue-chip drug stock boasts two quarters of accelerating earnings growth - a fundamental metr... | Medical-Ethical Drug industry group leader AbbVie ( ABBV ) surged more than 10% Friday after handily beating its Q4 profit and sales estimates . Amid renewed strength in the biotech and drug industry, Pfizer ( PFE ) is surging into multiyear-high territory Friday as volume tracked well above average. According to the I... | Medical-Ethical Drug industry group leader AbbVie ( ABBV ) surged more than 10% Friday after handily beating its Q4 profit and sales estimates . Amid renewed strength in the biotech and drug industry, Pfizer ( PFE ) is surging into multiyear-high territory Friday as volume tracked well above average. Pfizer shares, mea... | Medical-Ethical Drug industry group leader AbbVie ( ABBV ) surged more than 10% Friday after handily beating its Q4 profit and sales estimates . [ibd-display-video id=2382612 width=50 float=left autostart=true] The blue-chip drug stock boasts two quarters of accelerating earnings growth - a fundamental metric shared by... | Medical-Ethical Drug industry group leader AbbVie ( ABBV ) surged more than 10% Friday after handily beating its Q4 profit and sales estimates . Amid renewed strength in the biotech and drug industry, Pfizer ( PFE ) is surging into multiyear-high territory Friday as volume tracked well above average. In the most recent... |
25,729 | 2018-01-26 00:00:00 UTC | Earnings Reaction History: AbbVie Inc., 41.7% Follow-Through Indicator, 3.2% Sensitive | ABBV | https://www.nasdaq.com/articles/earnings-reaction-history-abbvie-inc-417-follow-through-indicator-32-sensitive-2018-01-26 | null | null | Expected Earnings Release: 01/26/2018, Premarket
Avg. Extended-Hours Dollar Volume: $6,461,569
AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect very active trading in the issue immediately following its quarterly earnings an... | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 57.1% Average next regular session additional gain: 1.9% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of... | Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close. Last 12 Qtrs Positive Only Price Reactions Percent of time added to... | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 57.1% Average next regular session additional gain: 1.9% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of... | Extended-Hours Dollar Volume: $6,461,569 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of limited value ... |
25,730 | 2018-01-25 00:00:00 UTC | Notable Thursday Option Activity: ASPS, ABBV, AMTD | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity-asps-abbv-amtd-2018-01-25 | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Altisource Portfolio Solutions SA (Symbol: ASPS), where a total of 1,484 contracts have traded so far, representing approximately 148,400 underlying shares. That amounts to about 78.8% of ASPS's average daily tr... | Particularly high volume was seen for the $116 strike call option expiring February 16, 2018 , with 11,542 contracts trading so far today, representing approximately 1.2 million underlying shares of ABBV. Below is a chart showing ASPS's trailing twelve month trading history, with the $25 strike highlighted in orange: A... | Below is a chart showing ASPS's trailing twelve month trading history, with the $25 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 32,753 contracts thus far today. Particularly high volume was seen for the $116 strike call option expiring February 16, 2018 , with 11,542 contract... | Particularly high volume was seen for the $116 strike call option expiring February 16, 2018 , with 11,542 contracts trading so far today, representing approximately 1.2 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $116 strike highlighted in orange: ... | Below is a chart showing ABBV's trailing twelve month trading history, with the $116 strike highlighted in orange: And TD Ameritrade Holding Corp (Symbol: AMTD) saw options trading volume of 19,866 contracts, representing approximately 2.0 million underlying shares or approximately 68.8% of AMTD's average daily trading... |
25,731 | 2018-01-25 00:00:00 UTC | Why AbbVie (ABBV) Might Surprise This Earnings Season | ABBV | https://www.nasdaq.com/articles/why-abbvie-abbv-might-surprise-this-earnings-season-2018-01-25 | null | null | Investors are always looking for stocks that are poised to beat at earnings season and AbbVie Inc.ABBV may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because AbbVieis seeing favorable earnings estimate revision activity as of late, ... | After all, analysts raising estimates right before earnings - with the most up-to-date information possible - is a pretty good indicator of some favorable trends underneath the surface for ABBV in this report. Given that ABBV has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this st... | Clearly, recent earnings estimate revisions suggest that good things are ahead for AbbVie, and that a beat might be in the cards for the upcoming report. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Investors are always looking for stocks tha... | This suggests that analysts have very recently bumped up their estimates for ABBV, giving the stock a Zacks Earnings ESP of +1.30% heading into earnings season. Given that ABBV has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always looki... | This suggests that analysts have very recently bumped up their estimates for ABBV, giving the stock a Zacks Earnings ESP of +1.30% heading into earnings season. Given that ABBV has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Clearly, recent earnings e... |
25,732 | 2018-01-25 00:00:00 UTC | Pre-Market Earnings Report for January 26, 2018 : ABBV, HON, NEE, CL, APD, COL, LEA, GNTX, HRC, POL, NEP, ABCB | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-january-26-2018-abbv-hon-nee-cl-apd-col-lea-gntx-hrc-pol-nep | null | null | The following companies are expected to report earnings prior to market open on 01/26/2018. Visit our Earnings Calendar for a full list of expected earnings releases.
AbbVie Inc. ( ABBV ) is reporting for the quarter ending December 31, 2017. The large cap pharmaceutical company's consensus earnings per share forecast ... | AbbVie Inc. ( ABBV ) is reporting for the quarter ending December 31, 2017. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABBV is 18.98 vs. an industry ratio of 17.70, implying that ... | Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABBV is 18.98 vs. an industry ratio of 17.70, implying that they will have a higher earnings growth than their competitors in the same industry. AbbVie Inc. ( ABBV ) is reporting for the quarter ending December 31, 2017. In the past year ABBV h... | Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABBV is 18.98 vs. an industry ratio of 17.70, implying that they will have a higher earnings growth than their competitors in the same industry. AbbVie Inc. ( ABBV ) is reporting for the quarter ending December 31, 2017. In the past year ABBV h... | AbbVie Inc. ( ABBV ) is reporting for the quarter ending December 31, 2017. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABBV is 18.98 vs. an industry ratio of 17.70, implying that ... |
25,733 | 2018-01-24 00:00:00 UTC | 3 Stocks to Help You Build Retirement Wealth | ABBV | https://www.nasdaq.com/articles/3-stocks-help-you-build-retirement-wealth-2018-01-24 | null | null | If you want to build retirement wealth, there are two great ways to do it. The first is that you can find stocks that should appreciate in value significantly. The second is that you can find stocks that pay out attractive dividends, which you can then use to reinvest for a greater overall return. An even better way to... | AbbVie hopes to achieve that big sales increase through existing products such as Imbruvica, Venclexta, Mavyret, and Zinbryta. Three top stocks that made the cut were AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , and Iron Mountain (NYSE: IRM) . AbbVie AbbVie didn't just beat the S&P 500 and Dow... | Three top stocks that made the cut were AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , and Iron Mountain (NYSE: IRM) . AbbVie AbbVie didn't just beat the S&P 500 and Dow Jones index es in 2017 -- it clobbered them. AbbVie expects to generate strong double-digit earnings growth through 2020. | Probably the only way AbbVie's dividend yield won't go higher is if the future dividend increases don't keep up with the stock appreciation -- exactly what happened last year. Even though AbbVie, Brookfield Infrastructure Partners, and Iron Mountain enjoyed great years in 2017, not every year will be that good. Three t... | Even though AbbVie, Brookfield Infrastructure Partners, and Iron Mountain enjoyed great years in 2017, not every year will be that good. Three top stocks that made the cut were AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , and Iron Mountain (NYSE: IRM) . AbbVie AbbVie didn't just beat the S&P 5... |
25,734 | 2018-01-24 00:00:00 UTC | Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto | ABBV | https://www.nasdaq.com/articles/novartis-nvs-q4-earnings-sales-top-on-cosentyx-entresto-2018-01-24 | null | null | Novartis AGNVS reported encouraging results for fourth-quarter 2017 wherein both earnings and revenues beat estimates driven by strong performance of Cosentyx and Entresto.
Novartis AG Price and EPS Surprise
Novartis AG Price and EPS Surprise | Novartis AG Quote
Fourth-quarter 2017 core earnings of $1.21 per share beat... | The proposed biosimilar version of AbbVie. Inc.'s ABBV Humira (adalimumab) has also been accepted for review by the FDA. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The proposed biosimilar version of AbbVie. Inc.'s AB... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The proposed biosimilar version of AbbVie. Inc.'s AB... | The proposed biosimilar version of AbbVie. Inc.'s ABBV Humira (adalimumab) has also been accepted for review by the FDA. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free... |
25,735 | 2018-01-24 00:00:00 UTC | The Zacks Analyst Blog Highlights: AbbVie, Merck & Co. and AstraZeneca | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-abbvie-merck-co.-and-astrazeneca-2018-01-24 | null | null | For Immediate Release
Chicago, IL - January 24, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include AbbVie Inc.ABBV , Merck & C... | Stocks recently featured in the blog include AbbVie Inc.ABBV , Merck & Co., Inc.MRK and AstraZeneca plcAZN . Our first pick is AbbVie Inc . AbbVie is scheduled to report results on Jan 26. | Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include AbbVie Inc.ABBV , Merck & Co., Inc.MRK and Ast... | Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include AbbVie Inc.ABBV , Merck & Co., Inc.MRK and Ast... | Stocks recently featured in the blog include AbbVie Inc.ABBV , Merck & Co., Inc.MRK and AstraZeneca plcAZN . Our first pick is AbbVie Inc . AbbVie is scheduled to report results on Jan 26. |
25,736 | 2018-01-24 00:00:00 UTC | See Which Of The Latest 13F Filers Holds AbbVie | ABBV | https://www.nasdaq.com/articles/see-which-latest-13f-filers-holds-abbvie-2018-01-24 | null | null | At Holdings Channel , we have reviewed the latest batch of the 24 most recent 13F filings for the 12/31/2017 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 13 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we procee... | At Holdings Channel , we have reviewed the latest batch of the 24 most recent 13F filings for the 12/31/2017 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 13 of these funds. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the... | At Holdings Channel , we have reviewed the latest batch of the 24 most recent 13F filings for the 12/31/2017 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 13 of these funds. Below, let's take a look at the change in ABBV positions, for this latest batch of 13F filers: In terms of shares owned... | Below, let's take a look at the change in ABBV positions, for this latest batch of 13F filers: In terms of shares owned, we count 3 of the above funds having increased existing ABBV positions from 09/30/2017 to 12/31/2017, with 4 having decreased their positions and 2 new positions. We then compared that number to the ... | Below, let's take a look at the change in ABBV positions, for this latest batch of 13F filers: In terms of shares owned, we count 3 of the above funds having increased existing ABBV positions from 09/30/2017 to 12/31/2017, with 4 having decreased their positions and 2 new positions. We then compared that number to the ... |
25,737 | 2018-01-24 00:00:00 UTC | Is a Beat in the Cards for AbbVie (ABBV) in Q4 Earnings? | ABBV | https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-abbvie-abbv-in-q4-earnings-2018-01-24 | null | null | We expect AbbVie Inc.ABBV to beat expectations when it reports fourth-quarter 2017 results on Jan 26 before the market opens. Last quarter, the company delivered a positive earnings surprise of 1.44%.
AbbVie's shares have soared 73.9% in a year's time, ahead of the industry 's rally of 24.6%.
Notably, AbbVie's earnings... | Notably, AbbVie's earnings history is quite impressive with the pharmaceuticals company outpacing estimates in three of the last four quarters and meeting the same in one. Significantly, on fourth-quarter conference call, investors' focus will also be on the performance and label expansion updates of AbbVie's another c... | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Other Stocks That Warrant a Look Here are some other health care stocks worth considering as per our model, these comprise the right combination of elements to beat on earnings this time around: Pfizer, Inc. PFE is scheduled to re... | Zacks Rank: AbbVie has a Zacks Rank #3, which increases the predictive power of ESP and together with a positive ESP, chances of beating estimates in the stock's upcoming release are always pegged higher. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Anal... | Zacks Rank: AbbVie has a Zacks Rank #3, which increases the predictive power of ESP and together with a positive ESP, chances of beating estimates in the stock's upcoming release are always pegged higher. We expect AbbVie Inc.ABBV to beat expectations when it reports fourth-quarter 2017 results on Jan 26 before the mar... |
25,738 | 2018-01-23 00:00:00 UTC | 3 Large Cap Pharma Stocks to Beat Earnings This Quarter | ABBV | https://www.nasdaq.com/articles/3-large-cap-pharma-stocks-to-beat-earnings-this-quarter-2018-01-23 | null | null | The fourth-quarter earnings season is in full swing and the trend so far appears impressive. Notably, 53 S&P 500 companies have posted results (as of Jan 19, 2018) with earnings up 11.7% on revenue growth of 7.5%, per the latest Earnings Preview . Also, 62.3% of these companies topped on earnings and revenues.
Focusing... | Our first pick is AbbVie Inc. ( ABBV ). AbbVie is scheduled to report results on Jan 26. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Our first pick is AbbVie Inc. ( ABBV ). AbbVie is scheduled to report results on Jan 26. | Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Our first pick is AbbVie Inc. ( ABBV ). AbbVie is scheduled to report results on Jan 26. | Our first pick is AbbVie Inc. ( ABBV ). AbbVie is scheduled to report results on Jan 26. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. |
25,739 | 2018-01-23 00:00:00 UTC | The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, AbbVie and Merck | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-alexion-pharmaceuticals-celgene-abbvie-and-merck-2018 | null | null | For Immediate Release
Chicago, IL - January 23, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Alexion Pharmaceuticals, In... | Stocks recently featured in the blog include Alexion Pharmaceuticals, Inc.ALXN , Celgene CorporationCELG , AbbVieABBV and MerckMRK . AbbVie: AbbVie, which is known for its blockbuster drug, Humira, is focused on the development of treatments across four primary therapeutic areas: immunology, oncology, virology and neur... | Click to get this free report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featu... | Click to get this free report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featu... | Stocks recently featured in the blog include Alexion Pharmaceuticals, Inc.ALXN , Celgene CorporationCELG , AbbVieABBV and MerckMRK . AbbVie: AbbVie, which is known for its blockbuster drug, Humira, is focused on the development of treatments across four primary therapeutic areas: immunology, oncology, virology and neur... |
25,740 | 2018-01-23 00:00:00 UTC | Will Core Segmental Growth Aid Stryker (SYK) in Q4 Earnings? | ABBV | https://www.nasdaq.com/articles/will-core-segmental-growth-aid-stryker-syk-in-q4-earnings-2018-01-23 | null | null | Stryker Corporation 's SYK fourth-quarter 2017 results are scheduled for release on Jan 30, 2018, after the market closes . In the said quarter, the company is expected to witness year-over-year revenue growth in all other business segments apart from Orthopedics, Medsurg and Neurotechnology and Spine.
Despite reportin... | AbbVie Inc. ABBV has an earnings ESP of +1.30% and a Zacks Rank #2. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bio-Techne Corp (TECH): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Fibrocell Science Inc (FCSC): Free Stock Analysis Report To read this ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bio-Techne Corp (TECH): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Fibrocell Science Inc (FCSC): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV has an earnings ES... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bio-Techne Corp (TECH): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Fibrocell Science Inc (FCSC): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV has an earnings ES... | AbbVie Inc. ABBV has an earnings ESP of +1.30% and a Zacks Rank #2. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bio-Techne Corp (TECH): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Fibrocell Science Inc (FCSC): Free Stock Analysis Report To read this ... |
25,741 | 2018-01-23 00:00:00 UTC | Novartis Announces Positive Results on Migraine Candidate | ABBV | https://www.nasdaq.com/articles/novartis-announces-positive-results-on-migraine-candidate-2018-01-23 | null | null | Novartis AGNVS announced positive results from the phase IIIb study, LIBERTY, which assessed the efficacy and safety of erenumab (AMG 334) 140mg in patients with episodic migraine who had experienced two to four previous preventive treatment failures, due to lack of efficacy or intolerable side effects.
The study met i... | Cosentyx has been strong and the company has grabbed market shares from rivals like AbbVie, Inc.'s ABBV Humira and Amgen's Enbrel. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Exelixis, Inc. (EXEL... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. Cosentyx has been strong and the company has grabbed ma... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. Cosentyx has been strong and the company has grabbed ma... | Cosentyx has been strong and the company has grabbed market shares from rivals like AbbVie, Inc.'s ABBV Humira and Amgen's Enbrel. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Exelixis, Inc. (EXEL... |
25,742 | 2018-01-23 00:00:00 UTC | Stocks Showing Improving Market Leadership: Grifols Earns 82 RS Rating | ABBV | https://www.nasdaq.com/articles/stocks-showing-improving-market-leadership-grifols-earns-82-rs-rating-2018-01-23 | null | null | On Tuesday, Grifols ( GRFS ) received a positive adjustment to its Relative Strength ( RS ) Rating , from 78 to 82.
[ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up agains... | AbbVie ( ABBV ) is the top-ranked stock within the group. On Tuesday, Grifols ( GRFS ) received a positive adjustment to its Relative Strength ( RS ) Rating , from 78 to 82. Over 100 years of market history reveals that the best-performing stocks typically have an 80 or better RS Rating as they launch their biggest cli... | AbbVie ( ABBV ) is the top-ranked stock within the group. On Tuesday, Grifols ( GRFS ) received a positive adjustment to its Relative Strength ( RS ) Rating , from 78 to 82. Biotech And Pharmaceutical Industry And Stock News IBD Stock Rating Upgrades: Rising Relative Strength Why Should You Use IBD's Relative Strength ... | AbbVie ( ABBV ) is the top-ranked stock within the group. [ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database. Biotech And Ph... | AbbVie ( ABBV ) is the top-ranked stock within the group. [ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database. Biotech And Ph... |
25,743 | 2018-01-22 00:00:00 UTC | Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season? | ABBV | https://www.nasdaq.com/articles/will-these-4-large-cap-drug-stocks-be-big-winners-earnings-season-2018-01-22-0 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
2017 was a good year for pharma and biotech stocks with the sector witnessing some positive developments that led to a much-awaited recovery.
Moreover, a significantly higher number of FDA approvals in 2017 has restored investor confidence in the sector. Th... | Large-Cap Drug Stocks Could Be Big Winners This Earnings Season: AbbVie Inc (ABBV) AbbVie Inc (NYSE: ABBV ) : AbbVie, which is known for its blockbuster drug, Humira, is focused on the development of treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. AbbVie will be report... | Large-Cap Drug Stocks Could Be Big Winners This Earnings Season: AbbVie Inc (ABBV) AbbVie Inc (NYSE: ABBV ) : AbbVie, which is known for its blockbuster drug, Humira, is focused on the development of treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. AbbVie will be report... | Large-Cap Drug Stocks Could Be Big Winners This Earnings Season: AbbVie Inc (ABBV) AbbVie Inc (NYSE: ABBV ) : AbbVie, which is known for its blockbuster drug, Humira, is focused on the development of treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. AbbVie will be report... | Large-Cap Drug Stocks Could Be Big Winners This Earnings Season: AbbVie Inc (ABBV) AbbVie Inc (NYSE: ABBV ) : AbbVie, which is known for its blockbuster drug, Humira, is focused on the development of treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. AbbVie will be report... |
25,744 | 2018-01-22 00:00:00 UTC | Healthcare ETFs to Watch As Q4 Earnings Unfold | ABBV | https://www.nasdaq.com/articles/healthcare-etfs-watch-q4-earnings-unfold-2018-01-22 | null | null | Healthcare is performing well with the start of the New Year thanks to encouraging industry trends and a favorable policy environment. Notably, popular ETFs like Health Care Select Sector SPDR Fund XLV , Vanguard Health Care ETF VHT , iShares U.S. Healthcare ETF IYH and Fidelity MSCI Health Care Index ETF FHLC have gai... | The bullish trend is likely to continue heading into the Q4 earnings season as some big names like Johnson and Johnson JNJ , Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , Gilead Sciences GILD and Bristol-Myers Squibb BMY are lined up to report this week and in the next. AbbVie has a Zacks Rank #3 and an Earnings ... | The bullish trend is likely to continue heading into the Q4 earnings season as some big names like Johnson and Johnson JNJ , Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , Gilead Sciences GILD and Bristol-Myers Squibb BMY are lined up to report this week and in the next. Click to get this free report Bristol-Myers... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report SPDR-HLTH CR (XLV): ETF R... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report SPDR-HLTH CR (XLV): ETF R... |
25,745 | 2018-01-22 00:00:00 UTC | What's in the Cards for Varian Medical (VAR) in Q1 Earnings? | ABBV | https://www.nasdaq.com/articles/whats-in-the-cards-for-varian-medical-var-in-q1-earnings-2018-01-22 | null | null | Varian Medical Systems Inc.VAR is set to report first-quarter fiscal 2018 results on Jan 24, after the market closes . In the previous quarter, the company reported adjusted earnings per share of $1.09, which missed the Zacks Consensus Estimate of $1.19. Further, adjusted earnings declined from $1.38 in the year-ago qu... | AbbVie Inc. ABBV has an Earnings ESP of +1.30% and a Zacks Rank #3. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie... | AbbVie Inc. ABBV has an Earnings ESP of +1.30% and a Zacks Rank #3. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock ... |
25,746 | 2018-01-22 00:00:00 UTC | Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season? | ABBV | https://www.nasdaq.com/articles/will-these-4-large-cap-drug-stocks-be-big-winners-earnings-season-2018-01-22 | null | null | 2017 was a good year for pharma and biotech stocks with the sector witnessing some positive developments that led to a much-awaited recovery.
A key reason for the sector's improved performance was the willingness of investors to look beyond the drug pricing controversy and focus more on fundamentals instead. Although t... | AbbVie ABBV : AbbVie, which is known for its blockbuster drug, Humira, is focused on the development of treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. AbbVie will be reporting its fourth quarter results on January 26. AbbVie's shares are up 71.6% over the last one yea... | Click to get this free report Sanofi (SNY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free S... | Click to get this free report Sanofi (SNY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free S... | AbbVie ABBV : AbbVie, which is known for its blockbuster drug, Humira, is focused on the development of treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. AbbVie will be reporting its fourth quarter results on January 26. AbbVie's shares are up 71.6% over the last one yea... |
25,747 | 2018-01-22 00:00:00 UTC | 3 Top Stocks Bloggers Are Raving Over Right Now | ABBV | https://www.nasdaq.com/articles/3-top-stocks-bloggers-are-raving-over-right-now-2018-01-22 | null | null | Most investors prefer to follow the recommendations of analysts that receive a lot of attention, analysts that work for leading financial institutions such as Goldman Sachs, Deutsche Bank and Credit Suisse (to name but a few). But there is a completely different group of financial experts who are also capable of delive... | AbbVie (ABBV) Over the last year, this Abbott Lab spin-off has exploded by 70%. AbbVie discovers, develops and markets both biopharmaceuticals and small molecule drugs. From a blogger perspective we can see that overall, bloggers are 82% bullish on ABBV right now. | AbbVie (ABBV) Over the last year, this Abbott Lab spin-off has exploded by 70%. AbbVie discovers, develops and markets both biopharmaceuticals and small molecule drugs. From a blogger perspective we can see that overall, bloggers are 82% bullish on ABBV right now. | These top bloggers call AbbVie a top dividend stock and one of the best big pharma stocks to by in 2018. AbbVie (ABBV) Over the last year, this Abbott Lab spin-off has exploded by 70%. AbbVie discovers, develops and markets both biopharmaceuticals and small molecule drugs. | Indeed, in the last three months top analysts have published four consecutive buy ratings on ABBV. AbbVie (ABBV) Over the last year, this Abbott Lab spin-off has exploded by 70%. AbbVie discovers, develops and markets both biopharmaceuticals and small molecule drugs. |
25,748 | 2018-01-22 00:00:00 UTC | MTUM, BA, ABBV, MCD: Large Inflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/mtum-ba-abbv-mcd-large-inflows-detected-etf-2018-01-22 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $405.6 million dollar inflow -- that's a 6.2% increase week over week in outstanding units (fr... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is off about 0.5%, AbbVie Inc (Symbol: ABBV) is up about 0.9%, and McDonald's Corp (Symbol: MCD) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel ... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is off about 0.5%, AbbVie Inc (Symbol: ABBV) is up about 0.9%, and McDonald's Corp (Symbol: MCD) is lower by about 0.1%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price perf... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is off about 0.5%, AbbVie Inc (Symbol: ABBV) is up about 0.9%, and McDonald's Corp (Symbol: MCD) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel ... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is off about 0.5%, AbbVie Inc (Symbol: ABBV) is up about 0.9%, and McDonald's Corp (Symbol: MCD) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel ... |
25,749 | 2018-01-21 00:00:00 UTC | 5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them | ABBV | https://www.nasdaq.com/articles/5-highest-growth-drugs-2018-and-who-will-get-rich-them-2018-01-21 | null | null | A billion dollars.
That's the minimum for the amount of additional sales a drug must have to make market research firm EvaluatePharma's ranking of the highest-growth drugs of 2018. EvaluatePharma looked at all of the drugs on the market to determine which should achieve the highest year-over-year sales growth. Five dru... | Mavyret is one of 10 drugs mentioned by AbbVie CEO Rick Gonzalez at the recent J.P. Morgan Healthcare Conference that the company believes will enable it to increase non-Humira sales to $35 billion by 2025. *Stock Advisor returns as of January 2, 2018 Keith Speights owns shares of AbbVie, Gilead Sciences, JPMorgan Chas... | Best pick to profit from these fast-growing drugs AbbVie, Bristol-Myers Squibb, Merck, and Pfizer all stand to rake in a lot more money this year thanks to these fast-growing drugs. Revenue of over $18 billion pretty much guaranteed AbbVie 's (NYSE: ABBV) autoimmune disease drug the top spot. However, AbbVie closed a d... | AbbVie didn't provide details of sales of the drug in the third quarter, but EvaluatePharma thinks Mavyret will grow sales by $1.18 billion in its first full year on the market. Best pick to profit from these fast-growing drugs AbbVie, Bristol-Myers Squibb, Merck, and Pfizer all stand to rake in a lot more money this y... | Ibrance AbbVie isn't the only big pharma with two drugs on the list. Revenue of over $18 billion pretty much guaranteed AbbVie 's (NYSE: ABBV) autoimmune disease drug the top spot. However, AbbVie closed a deal in 2017 that should give Humira clear sailing, at least in the U.S., for several more years. |
25,750 | 2018-01-21 00:00:00 UTC | Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc. | ABBV | https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-pfizer-inc-2018-01-21 | null | null | Your time horizon makes a huge difference when choosing between which stocks to buy. For example, suppose it's January 2011, and you're trying to decide between buying Gilead Sciences, Inc. (NASDAQ: GILD) or Pfizer Inc. (NYSE: PFE) . If your focus was only a 12-month period, Pfizer turned out to be the better pick. How... | Gilead CEO John Milligan even thinks that the entrance of AbbVie 's Mavyret on the market "sets the stage for smoothness to HCV sales for the future." *Stock Advisor returns as of January 2, 2018 Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. There's a good chance that Gilead emerges as one of the t... | Gilead CEO John Milligan even thinks that the entrance of AbbVie 's Mavyret on the market "sets the stage for smoothness to HCV sales for the future." *Stock Advisor returns as of January 2, 2018 Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. Even with HCV sales falling, the drugs, along with Gilead... | *Stock Advisor returns as of January 2, 2018 Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. Gilead CEO John Milligan even thinks that the entrance of AbbVie 's Mavyret on the market "sets the stage for smoothness to HCV sales for the future." However, if you had a longer time horizon such as five ye... | Gilead CEO John Milligan even thinks that the entrance of AbbVie 's Mavyret on the market "sets the stage for smoothness to HCV sales for the future." *Stock Advisor returns as of January 2, 2018 Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. There's also a really good chance that Gilead will use so... |
25,751 | 2018-01-19 00:00:00 UTC | Amgen/Allergan's Avastin Biosimilar Secures EU Approval | ABBV | https://www.nasdaq.com/articles/amgen-allergans-avastin-biosimilar-secures-eu-approval-2018-01-19 | null | null | Amgen, Inc.AMGN and partner Allergan AGN announced that the European Commission has granted marketing approval to its biosimilar version of Roche's RHHBY blockbuster cancer drug, Avastin (bevacizumab), Mvasi. The drug was approved in the United States in September.
Mvasi is approved in the EU for the treatment of multi... | Per a settlement agreement with AbbVie, Amgen will begin selling Amjevita in most countries in the EU this year and in the United States from January 2023. Amgen's biosimilar version of Abbvie's ABBV blockbuster rheumatoid arthritis drug Humira, Amjevita, was approved by the FDA in September 2016 and in the EU (trade n... | Amgen's biosimilar version of Abbvie's ABBV blockbuster rheumatoid arthritis drug Humira, Amjevita, was approved by the FDA in September 2016 and in the EU (trade name: Amgevita) in March 2017 for the same indications as Humira. (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc.... | (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Amgen's biosimilar version of Abbvie's ABBV blockbuster rheumatoid arthritis drug Humira, Amjevita, was approved by the FDA in September 2016 and i... | Amgen's biosimilar version of Abbvie's ABBV blockbuster rheumatoid arthritis drug Humira, Amjevita, was approved by the FDA in September 2016 and in the EU (trade name: Amgevita) in March 2017 for the same indications as Humira. Per a settlement agreement with AbbVie, Amgen will begin selling Amjevita in most countries... |
25,752 | 2018-01-19 00:00:00 UTC | The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-johnson-johnson-abbvie-amgen-novo-nordisk-and-zoetis | null | null | For Immediate Release
Chicago, IL - Jan 19, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Johnson & JohnsonJNJ , AbbVieAB... | In 2017, the company reported a series of positive news including promising data from several pivotal studies, regulatory approvals in the United States, Europe, and Japan for its competitive HCV medicine, Mavyret and FDA approval for the sixth indication for Imbruvica and settlement of its Humira patent disputes with ... | Click to get this free report Novo Nordisk A/S (NVO): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Zoetis Inc. (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. St... | In 2017, the company reported a series of positive news including promising data from several pivotal studies, regulatory approvals in the United States, Europe, and Japan for its competitive HCV medicine, Mavyret and FDA approval for the sixth indication for Imbruvica and settlement of its Humira patent disputes with ... | AbbVie The stock of the company was up 54.4% in 2017. Stocks recently featured in the blog include Johnson & JohnsonJNJ , AbbVieABBV , Amgen Inc.AMGN , Novo-NordiskNVO and ZoetisZTS . Here we present four companies, Johnson & Johnson, AbbVie, Zoetis and Novo Nordisk, which outperformed the industry last year and have t... |
25,753 | 2018-01-18 00:00:00 UTC | J&J (JNJ) Hits New 52-Week High: What's Driving the Stock? | ABBV | https://www.nasdaq.com/articles/jj-jnj-hits-new-52-week-high%3A-whats-driving-the-stock-2018-01-18 | null | null | Shares of Johnson & Johnson JNJ hit a new 52-week high of $148.32 on Jan 17 and eventually closed the day at $146.98. The stock hit the new high probably on a Reuters news which states that some Chinese bidders are planning to buy a J&J's diabetes care unit in the country in a deal which could be worth $4 billion
As it... | Investors should note that J&J markets Imbruvica in partnership with AbbVie, Inc. ABBV . Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis ... | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Investors should note that J&J marke... | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Investors should note that J&J marke... | Investors should note that J&J markets Imbruvica in partnership with AbbVie, Inc. ABBV . Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis ... |
25,754 | 2018-01-18 00:00:00 UTC | Can These 4 Large-Cap Drug Stocks Deliver an Encore in '18? | ABBV | https://www.nasdaq.com/articles/can-these-4-large-cap-drug-stocks-deliver-an-encore-in-18-2018-01-18 | null | null | Investing in sound large-cap pharma stocks seems judicious as they are fundamentally lucrative and ensure a steady stream of cash inflows for the investor.
The drug sector had a good run in 2017, bouncing back after drug pricing issues dampened its performance in 2016. Importantly, the sector saw a considerable increas... | Here we present four companies, Johnson & Johnson JNJ , AbbVie Inc. ABBV , Zoetis Inc. ZTS and Novo Nordisk A/S NVO , which outperformed the industry last year and have the potential to repeat the same performance in 2018. AbbVie The stock of the company was up 54.4% in 2017. AbbVie also expects several pivotal data re... | Here we present four companies, Johnson & Johnson JNJ , AbbVie Inc. ABBV , Zoetis Inc. ZTS and Novo Nordisk A/S NVO , which outperformed the industry last year and have the potential to repeat the same performance in 2018. Click to get this free report Novo Nordisk A/S (NVO): Free Stock Analysis Report Johnson & Johnso... | Click to get this free report Novo Nordisk A/S (NVO): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Zoetis Inc. (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. He... | Here we present four companies, Johnson & Johnson JNJ , AbbVie Inc. ABBV , Zoetis Inc. ZTS and Novo Nordisk A/S NVO , which outperformed the industry last year and have the potential to repeat the same performance in 2018. AbbVie The stock of the company was up 54.4% in 2017. AbbVie also expects several pivotal data re... |
25,755 | 2018-01-18 00:00:00 UTC | Top Research Reports for Apple, JPMorgan & AbbVie | ABBV | https://www.nasdaq.com/articles/top-research-reports-apple-jpmorgan-abbvie-2018-01-18 | null | null | Thursday, January 18, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), JPMorgan (JPM) and AbbVie (ABBV). These research reports have been hand-picked from the roughly 70 reports published... | Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), JPMorgan (JPM) and AbbVie (ABBV). Buy-rated AbbVie 's shares have gained +70.1% over the last one year, outperforming the Zacks Large Cap Pharmaceuticals industry, which has gained +22.9% over the same period. AbbVie's key ... | Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), JPMorgan (JPM) and AbbVie (ABBV). If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Apple (AAPL) Banks on Service Business and US Expansion Loan Growth, Inves... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Apple (AAPL) Banks on Service Business and US Expansion Loan Growth, Investment Banking to Support JPMorgan (JPM) Humira Driven Gains to Boost AbbVie (ABBV) , Pipeline in Focus Featured Reports BP Plc (BP)... | Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), JPMorgan (JPM) and AbbVie (ABBV). Buy-rated AbbVie 's shares have gained +70.1% over the last one year, outperforming the Zacks Large Cap Pharmaceuticals industry, which has gained +22.9% over the same period. AbbVie's key ... |
25,756 | 2018-01-17 00:00:00 UTC | AbbVie Named Top Dividend Stock With Insider Buying and 2.77% Yield (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-named-top-dividend-stock-insider-buying-and-277-yield-abbv-2018-01-17 | null | null | In this series, we look through the most recent Dividend Channel''DividendRank'' report, and then we cherry pick only those companies that have experienced insider buying within the past six months. The officers and directors of a company tend to have a unique insider's view of the business, and presumably the only rea... | The report also cited the strong quarterly dividend history at AbbVie Inc, and favorable long-term multi-year growth rates in key fundamental data points. One such company is AbbVie Inc (Symbol: ABBV), which saw buying by Director Edward J. Rapp. Back on July 31, Rapp invested $281,782.00 into 4,000 shares of ABBV, for... | By comparison, below is a table showing the prices at which insider buying was recorded over the last six months: The DividendRank report noted that among the coverage universe, ABBV shares displayed both attractive valuation metrics and strong profitability metrics. Below is a long-term dividend history chart for ABBV... | The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week range is $59.27 per share, with $103.72 as the 52 week high point - that compares with a last trade of $103.63. By comparison, below is a table showing the prices... | By comparison, below is a table showing the prices at which insider buying was recorded over the last six months: The DividendRank report noted that among the coverage universe, ABBV shares displayed both attractive valuation metrics and strong profitability metrics. One such company is AbbVie Inc (Symbol: ABBV), which... |
25,757 | 2018-01-17 00:00:00 UTC | Is Gilead Sciences, Inc. a Buy in 2018? | ABBV | https://www.nasdaq.com/articles/gilead-sciences-inc-buy-2018-2018-01-17 | null | null | On the last day of trading in 2016, Gilead Sciences ' (NASDAQ: GILD) stock price closed at $71.61 per share. Fast-forward one year, and Gilead's share price at the end of 2017 was $71.64. Over the course of a year, investors had gained all of three pennies per share. Of course, the return was better including dividend ... | In addition, Gilead now has a formidable competitor in AbbVie (NYSE: ABBV) . Although AbbVie's Viekira didn't take too much market share away from Gilead, its newer drug, Mavyret, could be a different story. Like Epclusa, Mavyret treats all genotypes of hepatitis C. Even Milligan acknowledges that there will be a head-... | Although AbbVie's Viekira didn't take too much market share away from Gilead, its newer drug, Mavyret, could be a different story. In addition, Gilead now has a formidable competitor in AbbVie (NYSE: ABBV) . Like Epclusa, Mavyret treats all genotypes of hepatitis C. Even Milligan acknowledges that there will be a head-... | In addition, Gilead now has a formidable competitor in AbbVie (NYSE: ABBV) . Although AbbVie's Viekira didn't take too much market share away from Gilead, its newer drug, Mavyret, could be a different story. Like Epclusa, Mavyret treats all genotypes of hepatitis C. Even Milligan acknowledges that there will be a head-... | In addition, Gilead now has a formidable competitor in AbbVie (NYSE: ABBV) . Although AbbVie's Viekira didn't take too much market share away from Gilead, its newer drug, Mavyret, could be a different story. Like Epclusa, Mavyret treats all genotypes of hepatitis C. Even Milligan acknowledges that there will be a head-... |
25,758 | 2018-01-16 00:00:00 UTC | Novartis (NVS) Announces Acceptance of Humira BLA by the FDA | ABBV | https://www.nasdaq.com/articles/novartis-nvs-announces-acceptance-of-humira-bla-by-the-fda-2018-01-16 | null | null | Novartis AGNVS generic arm, Sandoz announced that the FDA accepted its Biologics License Application (BLA) for the proposed biosimilar of AbbVie, Inc. ABBV Humira.
The biosimilar was submitted under the 351 (k) pathway.
The drug is already approved for the treatment of a number of inflammatory diseases including rheuma... | Novartis AGNVS generic arm, Sandoz announced that the FDA accepted its Biologics License Application (BLA) for the proposed biosimilar of AbbVie, Inc. ABBV Humira. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Ana... | Novartis AGNVS generic arm, Sandoz announced that the FDA accepted its Biologics License Application (BLA) for the proposed biosimilar of AbbVie, Inc. ABBV Humira. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Ana... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis AGNVS generic arm, Sandoz announced that the F... | Novartis AGNVS generic arm, Sandoz announced that the FDA accepted its Biologics License Application (BLA) for the proposed biosimilar of AbbVie, Inc. ABBV Humira. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Ana... |
25,759 | 2018-01-12 00:00:00 UTC | SPY, BA, DIS, ABBV: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/spy-ba-dis-abbv-etf-inflow-alert-2018-01-12 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P 500 ETF (Symbol: SPY) where we have detected an approximate $1.0 billion dollar inflow -- that's a 0.4% increase week over week in outstanding units (from 1,014,282,116 to 1,017,98... | Among the largest underlying components of SPY, in trading today Boeing Co. (Symbol: BA) is up about 1.5%, Walt Disney Co. (Symbol: DIS) is up about 0.3%, and AbbVie Inc (Symbol: ABBV) is up by about 0.4%. For a complete list of holdings, visit the SPY Holdings page » The chart below shows the one year price performanc... | Among the largest underlying components of SPY, in trading today Boeing Co. (Symbol: BA) is up about 1.5%, Walt Disney Co. (Symbol: DIS) is up about 0.3%, and AbbVie Inc (Symbol: ABBV) is up by about 0.4%. For a complete list of holdings, visit the SPY Holdings page » The chart below shows the one year price performanc... | Among the largest underlying components of SPY, in trading today Boeing Co. (Symbol: BA) is up about 1.5%, Walt Disney Co. (Symbol: DIS) is up about 0.3%, and AbbVie Inc (Symbol: ABBV) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one... | Among the largest underlying components of SPY, in trading today Boeing Co. (Symbol: BA) is up about 1.5%, Walt Disney Co. (Symbol: DIS) is up about 0.3%, and AbbVie Inc (Symbol: ABBV) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one... |
25,760 | 2018-01-12 00:00:00 UTC | 3 of the Best Dividend Aristocrats for Retirement | ABBV | https://www.nasdaq.com/articles/3-best-dividend-aristocrats-retirement-2018-01-12 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Retirement investing is a bit different from regular investing, and not because it depends more on dividend investing. See, we've been led to believe inflation is 3%, when it's really closer to 10%. That means that retired investors don't think they need st... | Dividend Aristocrats for Retirement: AbbVie Inc (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield: 2.8% AbbVie Inc (NYSE: ABBV ) is the spinoff from Abbott Laboratories (NYSE: ABT ). ABBV in particular is in areas that show no signs of slowing down: immunology, oncology and virology therapies. ABBV is... | Dividend Aristocrats for Retirement: AbbVie Inc (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield: 2.8% AbbVie Inc (NYSE: ABBV ) is the spinoff from Abbott Laboratories (NYSE: ABT ). ABBV in particular is in areas that show no signs of slowing down: immunology, oncology and virology therapies. ABBV is... | Dividend Aristocrats for Retirement: AbbVie Inc (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield: 2.8% AbbVie Inc (NYSE: ABBV ) is the spinoff from Abbott Laboratories (NYSE: ABT ). ABBV in particular is in areas that show no signs of slowing down: immunology, oncology and virology therapies. ABBV is... | Dividend Aristocrats for Retirement: AbbVie Inc (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield: 2.8% AbbVie Inc (NYSE: ABBV ) is the spinoff from Abbott Laboratories (NYSE: ABT ). ABBV in particular is in areas that show no signs of slowing down: immunology, oncology and virology therapies. ABBV is... |
25,761 | 2018-01-11 00:00:00 UTC | Miles White's Bold Moves Made Abbott Laboratories A Global Force | ABBV | https://www.nasdaq.com/articles/miles-whites-bold-moves-made-abbott-laboratories-global-force-2018-01-11 | null | null | When Miles White was named CEO of Abbott Laboratories ( ABT ) in 1998 at 43, he was the youngest head of a major health care company.
Today, he's one of the longest-serving chiefs in health care and has made a reputation as a master strategist, known for making bold moves at Abbott. And none was more dramatic than when... | And none was more dramatic than when he spun off the research-based pharmaceutical half of the firm as AbbVie ( ABBV ) in 2013. The result: Abbott's stock has since risen from 24 a share to around 59 a share, giving it a market cap of about $102 billion, while AbbVie's shares increased from 33 a share to near 100 a sha... | The New Abbott After separating from AbbVie in January 2013, the new Abbott emerged with a focus on not only diagnostic products and services, but medical devices, nutritional lines and branded generic medicines. And none was more dramatic than when he spun off the research-based pharmaceutical half of the firm as AbbV... | And none was more dramatic than when he spun off the research-based pharmaceutical half of the firm as AbbVie ( ABBV ) in 2013. The result: Abbott's stock has since risen from 24 a share to around 59 a share, giving it a market cap of about $102 billion, while AbbVie's shares increased from 33 a share to near 100 a sha... | In 2016, now part of AbbVie, it made $16.1 billion in sales, making it the best-selling drug in the world. And none was more dramatic than when he spun off the research-based pharmaceutical half of the firm as AbbVie ( ABBV ) in 2013. The result: Abbott's stock has since risen from 24 a share to around 59 a share, givi... |
25,762 | 2018-01-11 00:00:00 UTC | Here's What AbbVie's Management Just Said About Its Future | ABBV | https://www.nasdaq.com/articles/heres-what-abbvies-management-just-said-about-its-future-2018-01-11 | null | null | AbbVie Inc. (NYSE: ABBV) was a top performer last year, thanks to growing confidence that its best-selling drug, Humira, can escape biosimilar competition until 2022. This week, AbbVie's management fueled investor optimism further by outlining financials for the future that included a bullish outlook for Humira sales a... | This week, AbbVie's management fueled investor optimism further by outlining financials for the future that included a bullish outlook for Humira sales and billions in revenue from new drugs. The Patent Office's decision prompted another AbbVie competitor, Amgen (NASDAQ: AMGN) , to agree shortly thereafter to a non-exc... | This week, AbbVie's management fueled investor optimism further by outlining financials for the future that included a bullish outlook for Humira sales and billions in revenue from new drugs. The combination of top-line growth from AbbVie's pipeline and dividend growth makes AbbVie a great stock to consider for both gr... | This week, AbbVie's management fueled investor optimism further by outlining financials for the future that included a bullish outlook for Humira sales and billions in revenue from new drugs. What management's saying Amgen does have the right to begin selling its Humira biosimilar in Europe this year, but AbbVie still ... | This week, AbbVie's management fueled investor optimism further by outlining financials for the future that included a bullish outlook for Humira sales and billions in revenue from new drugs. What management's saying Amgen does have the right to begin selling its Humira biosimilar in Europe this year, but AbbVie still ... |
25,763 | 2018-01-11 00:00:00 UTC | Jeff Sessions is Taking Some Steam Out of the Marijuana Stocks Rally | ABBV | https://www.nasdaq.com/articles/jeff-sessions-taking-some-steam-out-marijuana-stocks-rally-2018-01-11 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Australia earlier this month joined the growing list of nations that have legalized medical marijuana. And as more countries are added to the list - as well as a smaller number approving or decriminalizing recreational use - many investors see upside remain... | Cannabis-Related Investments Investors may pickAbbVie Inc (NYSE: ABBV ), due to its cannabis-based drug Marinol, or Scotts Miracle-Gro Co (NYSE: SMG ), since its fertilizers facilitate the growth of marijuana plants. And as more countries are added to the list - as well as a smaller number approving or decriminalizing ... | Cannabis-Related Investments Investors may pickAbbVie Inc (NYSE: ABBV ), due to its cannabis-based drug Marinol, or Scotts Miracle-Gro Co (NYSE: SMG ), since its fertilizers facilitate the growth of marijuana plants. The strong market interest in companies producing cannabis may give GWPH stock a positive lift, too. In... | Cannabis-Related Investments Investors may pickAbbVie Inc (NYSE: ABBV ), due to its cannabis-based drug Marinol, or Scotts Miracle-Gro Co (NYSE: SMG ), since its fertilizers facilitate the growth of marijuana plants. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Australia earlier this month joined the ... | Cannabis-Related Investments Investors may pickAbbVie Inc (NYSE: ABBV ), due to its cannabis-based drug Marinol, or Scotts Miracle-Gro Co (NYSE: SMG ), since its fertilizers facilitate the growth of marijuana plants. Its Sativex is the first cannabis-derived drug that won market approval in any country. Valuation Analy... |
25,764 | 2018-01-11 00:00:00 UTC | Earnings Season Watch List: AbbVie | ABBV | https://www.nasdaq.com/articles/earnings-season-watch-list-abbvie-2018-01-11 | null | null | To get ready for earnings season, focus on stocks in or near a potential buy range ahead of their next quarterly report. AbbVie ( ABBV ) currently fits that bill. The company is expected to report on Jan. 25. It's trading around 1% above a 98.36 buy point from a second-stage flat base .
[ibd-display-video id=2360792 wi... | See How IBD Helps You Make More Money In Stocks AbbVie saw both earnings and sales growth rise last quarter. AbbVie ( ABBV ) currently fits that bill. AbbVie has a 96 Composite Rating and holds the No. | AbbVie ( ABBV ) currently fits that bill. See How IBD Helps You Make More Money In Stocks AbbVie saw both earnings and sales growth rise last quarter. AbbVie has a 96 Composite Rating and holds the No. | See How IBD Helps You Make More Money In Stocks AbbVie saw both earnings and sales growth rise last quarter. AbbVie ( ABBV ) currently fits that bill. AbbVie has a 96 Composite Rating and holds the No. | AbbVie ( ABBV ) currently fits that bill. See How IBD Helps You Make More Money In Stocks AbbVie saw both earnings and sales growth rise last quarter. AbbVie has a 96 Composite Rating and holds the No. |
25,765 | 2018-01-11 00:00:00 UTC | Why TG Therapeutics Rallied 15.7% Today | ABBV | https://www.nasdaq.com/articles/why-tg-therapeutics-rallied-157-today-2018-01-11 | null | null | What happened
Shares of TG Therapeutics (NASDAQ: TGTX) jumped 15.7% Thursday after management updated the progress it's making with its cancer drug pipeline at the JP Morgan healthcare conference earlier in the day.
So what
The clinical-stage biotech's stock tumbled last fall because investors' optimism began to dim ab... | In early 2017, expectations for such an early FDA OK swelled after TG Therapeutics reported that adding TG-1101, or ublituximab, to AbbVie 's (NYSE: ABBV) and Johnson & Johnson 's (NYSE: JNJ) top-selling Imbruvica resulted in an objective response rate (ORR) of 78% in chronic lymphocytic leukemia patients. What happene... | In early 2017, expectations for such an early FDA OK swelled after TG Therapeutics reported that adding TG-1101, or ublituximab, to AbbVie 's (NYSE: ABBV) and Johnson & Johnson 's (NYSE: JNJ) top-selling Imbruvica resulted in an objective response rate (ORR) of 78% in chronic lymphocytic leukemia patients. What happene... | In early 2017, expectations for such an early FDA OK swelled after TG Therapeutics reported that adding TG-1101, or ublituximab, to AbbVie 's (NYSE: ABBV) and Johnson & Johnson 's (NYSE: JNJ) top-selling Imbruvica resulted in an objective response rate (ORR) of 78% in chronic lymphocytic leukemia patients. What happene... | In early 2017, expectations for such an early FDA OK swelled after TG Therapeutics reported that adding TG-1101, or ublituximab, to AbbVie 's (NYSE: ABBV) and Johnson & Johnson 's (NYSE: JNJ) top-selling Imbruvica resulted in an objective response rate (ORR) of 78% in chronic lymphocytic leukemia patients. What happene... |
25,766 | 2018-01-11 00:00:00 UTC | 7 Must-See Numbers from AbbVie's J. P. Morgan Presentation | ABBV | https://www.nasdaq.com/articles/7-must-see-numbers-abbvies-j-p-morgan-presentation-2018-01-11 | null | null | One year ago, AbbVie (NYSE: ABBV) CEO Rick Gonzalez spoke at the J. P. Morgan Healthcare Conference. He highlighted seven reasons that I viewed as reasons why AbbVie stock could soar in 2017 . And that's exactly what happened. With its dividends included, AbbVie generated a total return last year of 60%.
Gonzalez prese... | Gonzalez reiterated the outlook that AbbVie shared a few months ago projecting that Humira's global sales will approach $21 billion by 2020. *Stock Advisor returns as of January 2, 2018 Keith Speights owns shares of AbbVie, Gilead Sciences, and JPMorgan Chase. One year ago, AbbVie (NYSE: ABBV) CEO Rick Gonzalez spoke a... | With its dividends included, AbbVie generated a total return last year of 60%. Key takeaway My key takeaway from Rick Gonzalez's presentation at the J. P. Morgan conference was that AbbVie's plan seems achievable. One year ago, AbbVie (NYSE: ABBV) CEO Rick Gonzalez spoke at the J. P. Morgan Healthcare Conference. | Gonzalez stated that the drug is on track to generate peak revenue for AbbVie of at least $7 billion. Gonzalez reiterated the outlook that AbbVie shared a few months ago projecting that Humira's global sales will approach $21 billion by 2020. To put this number in perspective, AbbVie will probably report revenue of aro... | For AbbVie, the most important number to know about the company's track record is three. $7 billion One key ingredient to AbbVie's future growth is Imbruvica. One year ago, AbbVie (NYSE: ABBV) CEO Rick Gonzalez spoke at the J. P. Morgan Healthcare Conference. |
25,767 | 2018-01-10 00:00:00 UTC | AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for January 11, 2018 | ABBV | https://www.nasdaq.com/articles/abbvie-inc-abbv-ex-dividend-date-scheduled-january-11-2018-2018-01-10 | null | null | AbbVie Inc. ( ABBV ) will begin trading ex-dividend on January 11, 2018. A cash dividend payment of $0.71 per share is scheduled to be paid on February 15, 2018. Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 10.94% increase over prior divide... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABBV's forecasted earnings growth in 2017 as 15.12%, compared to an industry average of 6.2%. For more information on the declaration, record and payment dates, visit the ABBV Divi... | The following ETF(s) have ABBV as a top-10 holding: First Trust Nasdaq Pharmaceuticals ETF ( FTXH ) iShares U.S. Healthcare ETF ( IYH ) Vanguard Health Care ETF ( VHT ) First Trust Hedged BuyWrite Income ETF ( FTLB ) First Trust BuyWrite Income ETF ( FTHI ). The views and opinions expressed herein are the views and opi... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABBV Dividend History page. The following ETF(s) have ABBV as a top-10 holding: First Trust Nasdaq Pharmaceuticals ETF ( FTXH ) iShares U... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. AbbVie Inc. ( ABBV ) will begin trading ex-dividend on January 11, 2018. The previous trading day's last sale of ABBV was $100.24, representing a -1.03% decrease from the 52 week high of $101.28 and a 69.12% increa... |
25,768 | 2018-01-10 00:00:00 UTC | Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus | ABBV | https://www.nasdaq.com/articles/biotech-stock-roundup-celgene-acquire-impact-jp-morgan-healthcare-conference-focus-2018-01 | null | null | This week, the focus is on the 36th annual J.P. Morgan healthcare conference where several biotech and pharma companies provided a preliminary look at their results for 2017 and have also provided pipeline updates as well as their outlooks for 2018. Meanwhile, Celgene CELG was in the news with the company announcing it... | AbbVie Eczema Drug Gets BTD: AbbVie's ABBV investigational, once-daily oral JAK1-selective inhibitor, upadacitinib, has been granted Breakthrough Therapy Designation ("BTD") by the FDA for use in adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy. Upadacitinib is scheduled ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis ... | AbbVie Eczema Drug Gets BTD: AbbVie's ABBV investigational, once-daily oral JAK1-selective inhibitor, upadacitinib, has been granted Breakthrough Therapy Designation ("BTD") by the FDA for use in adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy. Upadacitinib is scheduled ... |
25,769 | 2018-01-10 00:00:00 UTC | Better Stock: AbbVie Inc (ABBV) vs. Johnson & Johnson (JNJ) | ABBV | https://www.nasdaq.com/articles/better-stock-abbvie-inc-abbv-vs-johnson-johnson-jnj-2018-01-10 | null | null | The last five years have been kind to nearly all investors. But health-focused companies like Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) have been particularly profitable indeed. Inclusive of dividends, these two have more than doubled and tripled, respectively.
But which stock is the better buy today? There... | But health-focused companies like Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) have been particularly profitable indeed. AbbVie's key moat comes in the form of the patents that the company has on key drugs. Those patents came in handy in late 2017 when AbbVie got Amgen to back off plans to offer a drug similar... | AbbVie's key moat comes in the form of the patents that the company has on key drugs. But when growth is taken into consideration via the PEG Ratio, AbbVie trades at a significant discount to Johnson & Johnson. But health-focused companies like Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) have been particularl... | But health-focused companies like Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) have been particularly profitable indeed. Perhaps I'm being a bit more conservative by siding with the slower growth company, but I believe Johnson & Johnson's moat and financial fortitude are enough to give it an edge over AbbVie's... | But health-focused companies like Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) have been particularly profitable indeed. AbbVie's key moat comes in the form of the patents that the company has on key drugs. Those patents came in handy in late 2017 when AbbVie got Amgen to back off plans to offer a drug similar... |
25,770 | 2018-01-09 00:00:00 UTC | 4 Best Marijuana Stocks to Play the Green Rush | ABBV | https://www.nasdaq.com/articles/4-best-marijuana-stocks-to-play-the-green-rush-2018-01-09 | null | null | Whether its eating a gooey, chocolatey brownie or taking a few hits off a freshly rolled joint, it's common knowledge that a lot of people like to get high. Many investors, however, have yet to "light up." Some hesitate from adding marijuana stocks to their portfolio on apprehensions that pot companies are involved in ... | AbbVie Inc. ABBV is a biopharmaceutical company that already has a cannabis-based drug approved by the FDA. Click to get this free report Bank of America Corporation (BAC): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Insys Therapeutics, Inc. (INSY): Free Stock Analysis Report Corbus Pharma... | Click to get this free report Bank of America Corporation (BAC): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Insys Therapeutics, Inc. (INSY): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report Zynerba Pharmaceuticals, Inc. (ZYNE): Free Stock... | Click to get this free report Bank of America Corporation (BAC): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Insys Therapeutics, Inc. (INSY): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report Zynerba Pharmaceuticals, Inc. (ZYNE): Free Stock... | AbbVie Inc. ABBV is a biopharmaceutical company that already has a cannabis-based drug approved by the FDA. Click to get this free report Bank of America Corporation (BAC): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Insys Therapeutics, Inc. (INSY): Free Stock Analysis Report Corbus Pharma... |
25,771 | 2018-01-09 00:00:00 UTC | Ex-Dividend Reminder: Patterson Companies, AbbVie and Abbott Laboratories | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder-patterson-companies-abbvie-and-abbott-laboratories-2018-01-09 | null | null | Looking at the universe of stocks we cover at Dividend Channel , on 1/11/18, Patterson Companies Inc (Symbol: PDCO), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Patterson Companies Inc will pay its quarterly dividend of $0.26 on 1/... | If they do continue, the current estimated yields on annualized basis would be 2.77% for Patterson Companies Inc, 2.85% for AbbVie Inc, and 1.90% for Abbott Laboratories. Looking at the universe of stocks we cover at Dividend Channel , on 1/11/18, Patterson Companies Inc (Symbol: PDCO), AbbVie Inc (Symbol: ABBV), and A... | Looking at the universe of stocks we cover at Dividend Channel , on 1/11/18, Patterson Companies Inc (Symbol: PDCO), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Patterson Companies Inc will pay its quarterly dividend of $0.26 on 1/... | Looking at the universe of stocks we cover at Dividend Channel , on 1/11/18, Patterson Companies Inc (Symbol: PDCO), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Patterson Companies Inc will pay its quarterly dividend of $0.26 on 1/... | Looking at the universe of stocks we cover at Dividend Channel , on 1/11/18, Patterson Companies Inc (Symbol: PDCO), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. If they do continue, the current estimated yields on annualized basis ... |
25,772 | 2018-01-09 00:00:00 UTC | AbbVie's Upadacitinib Gains Breakthrough Therapy Designation | ABBV | https://www.nasdaq.com/articles/abbvies-upadacitinib-gains-breakthrough-therapy-designation-2018-01-09 | null | null | AbbVieABBV announced that the FDA has granted Breakthrough Therapy Designation ("BTD") to its investigational JAK1 inhibitor, upadacitinib (ABT-494) for the treatment of severe atopic dermatitis
The designation aims to expedite the development and review of drugs intended to treat serious or life-threatening conditions... | AbbVieABBV announced that the FDA has granted Breakthrough Therapy Designation ("BTD") to its investigational JAK1 inhibitor, upadacitinib (ABT-494) for the treatment of severe atopic dermatitis The designation aims to expedite the development and review of drugs intended to treat serious or life-threatening conditions... | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Stocks to Consider AbbVie carries a Zacks Rank #3 (Hold). Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Celldex ... | AbbVieABBV announced that the FDA has granted Breakthrough Therapy Designation ("BTD") to its investigational JAK1 inhibitor, upadacitinib (ABT-494) for the treatment of severe atopic dermatitis The designation aims to expedite the development and review of drugs intended to treat serious or life-threatening conditions... | AbbVieABBV announced that the FDA has granted Breakthrough Therapy Designation ("BTD") to its investigational JAK1 inhibitor, upadacitinib (ABT-494) for the treatment of severe atopic dermatitis The designation aims to expedite the development and review of drugs intended to treat serious or life-threatening conditions... |
25,773 | 2018-01-09 00:00:00 UTC | Notable Tuesday Option Activity: MCK, ABBV, BIIB | ABBV | https://www.nasdaq.com/articles/notable-tuesday-option-activity-mck-abbv-biib-2018-01-09 | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in McKesson Corp (Symbol: MCK), where a total volume of 12,067 contracts has been traded thus far today, a contract volume which is representative of approximately 1.2 million underlying shares (given that... | Particularly high volume was seen for the $105 strike call option expiring January 19, 2018 , with 10,591 contracts trading so far today, representing approximately 1.1 million underlying shares of ABBV. Below is a chart showing MCK's trailing twelve month trading history, with the $165 strike highlighted in orange: Ab... | Below is a chart showing MCK's trailing twelve month trading history, with the $165 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 32,708 contracts thus far today. Particularly high volume was seen for the $105 strike call option expiring January 19, 2018 , with 10,591 contracts... | Particularly high volume was seen for the $105 strike call option expiring January 19, 2018 , with 10,591 contracts trading so far today, representing approximately 1.1 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $105 strike highlighted in orange: A... | That number of contracts represents approximately 3.3 million underlying shares, working out to a sizeable 78% of ABBV's average daily trading volume over the past month, of 4.2 million shares. Below is a chart showing ABBV's trailing twelve month trading history, with the $105 strike highlighted in orange: And Biogen ... |
25,774 | 2018-01-09 00:00:00 UTC | Is AbbVie Stock Still A Strong Buy? | ABBV | https://www.nasdaq.com/articles/abbvie-stock-still-strong-buy-2018-01-09 | null | null | What happened
Large cap stocks that come with top flight dividends don't normally gain 54% in a single year. However, that's exactly what the dividend aristocrat AbbVie (NYSE: ABBV) did in 2017, according to data from S&P Global Market Intelligence . Thanks to a global patent resolution with Amgen (NASDAQ: AMGN) that r... | Thanks to a global patent resolution with Amgen (NASDAQ: AMGN) that removed the immediate threat of copycat versions of Humira entering the U.S. market, AbbVie's stock took off like a rocket last year. So what The key takeaway is that AbbVie now has an extra few years to flesh out its oncology portfolio in an effort to... | So, despite AbbVie's monstrous rise in 2017, this top dividend and growth stock is arguably still a compelling buy at current levels. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. However, that's exactly what the dividend aristocrat... | Thanks to a global patent resolution with Amgen (NASDAQ: AMGN) that removed the immediate threat of copycat versions of Humira entering the U.S. market, AbbVie's stock took off like a rocket last year. So, despite AbbVie's monstrous rise in 2017, this top dividend and growth stock is arguably still a compelling buy at ... | Thanks to a global patent resolution with Amgen (NASDAQ: AMGN) that removed the immediate threat of copycat versions of Humira entering the U.S. market, AbbVie's stock took off like a rocket last year. So, despite AbbVie's monstrous rise in 2017, this top dividend and growth stock is arguably still a compelling buy at ... |
25,775 | 2018-01-08 00:00:00 UTC | Galapagos Reports Topline Data From Osteoarthritis Study | ABBV | https://www.nasdaq.com/articles/galapagos-reports-topline-data-from-osteoarthritis-study-2018-01-08 | null | null | Galapagos NVGLPG announced positive top-line data from phase Ib study evaluating its osteoarthritis ("OA") candidate, GLPG1972. The candidate reduced the level of ARGS neoepitope, a cartilage breakdown biomarker, by more than half in its highest dosage.
Shares of the company have risen 43.1% in the past year, outperfor... | The company has three CF candidate including GLPG2222, which are being developed in partnership with AbbVie Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Re... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report To read this article on Zacks.com click here. The company has three... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report To read this article on Zacks.com click here. The company has three... | The company has three CF candidate including GLPG2222, which are being developed in partnership with AbbVie Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Re... |
25,776 | 2018-01-07 00:00:00 UTC | 5 Biggest New Drugs of 2018 -- and How You Can Profit From Their Makers | ABBV | https://www.nasdaq.com/articles/5-biggest-new-drugs-2018-and-how-you-can-profit-their-makers-2018-01-07 | null | null | Get ready for a wave of new blockbuster drugs in 2018.
At least nine new drugs are expected to launch this year that have the potential for sales to top $1 billion by 2022, according to market research firm EvaluatePharma. Gilead Sciences (NASDAQ: GILD) , Novo Nordisk (NYSE: NVO) , Incyte (NASDAQ: INCY) , AbbVie (NYSE:... | Gilead Sciences (NASDAQ: GILD) , Novo Nordisk (NYSE: NVO) , Incyte (NASDAQ: INCY) , AbbVie (NYSE: ABBV) , and Celgene (NASDAQ: CELG) stand to make plenty of money from five of those drugs, assuming everything goes smoothly with the regulatory approval process. Rova-T AbbVie already claims a tremendously successful canc... | Gilead Sciences (NASDAQ: GILD) , Novo Nordisk (NYSE: NVO) , Incyte (NASDAQ: INCY) , AbbVie (NYSE: ABBV) , and Celgene (NASDAQ: CELG) stand to make plenty of money from five of those drugs, assuming everything goes smoothly with the regulatory approval process. Rova-T AbbVie already claims a tremendously successful canc... | Gilead Sciences (NASDAQ: GILD) , Novo Nordisk (NYSE: NVO) , Incyte (NASDAQ: INCY) , AbbVie (NYSE: ABBV) , and Celgene (NASDAQ: CELG) stand to make plenty of money from five of those drugs, assuming everything goes smoothly with the regulatory approval process. Rova-T AbbVie already claims a tremendously successful canc... | Gilead Sciences (NASDAQ: GILD) , Novo Nordisk (NYSE: NVO) , Incyte (NASDAQ: INCY) , AbbVie (NYSE: ABBV) , and Celgene (NASDAQ: CELG) stand to make plenty of money from five of those drugs, assuming everything goes smoothly with the regulatory approval process. Rova-T AbbVie already claims a tremendously successful canc... |
25,777 | 2018-01-07 00:00:00 UTC | 2 Top Dividend Stocks to Buy in 2018 | ABBV | https://www.nasdaq.com/articles/2-top-dividend-stocks-buy-2018-2018-01-07 | null | null | Dividend stocks are a critical part of a well-structured portfolio because of their ability to generate passive sources of income, or alternatively, compound returns on capital via a dividend reinvestment plan . Picking top dividend stocks , though, is anything but a straightforward process.
The good news is that the b... | Biopharmaceutical giants like AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) , after all, both possess an intriguing mix of strong free cash flows, exceptional dividend track records, and better-than-average growth prospects over the next decade. Top of its class AbbVie is a solid dividend stock to buy (or continue holdi... | Biopharmaceutical giants like AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) , after all, both possess an intriguing mix of strong free cash flows, exceptional dividend track records, and better-than-average growth prospects over the next decade. Top of its class AbbVie is a solid dividend stock to buy (or continue holdi... | Biopharmaceutical giants like AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) , after all, both possess an intriguing mix of strong free cash flows, exceptional dividend track records, and better-than-average growth prospects over the next decade. While top-flight dividend programs are unusual in the pharma space because ... | AbbVie is arguably worth buying because of its generous dividend yield of 2.94%, rapidly growing footprint in the high-value oncology market, and the substantially lower risk of copycat versions of Humira breaking into the all-important U.S. market this year. Biopharmaceutical giants like AbbVie (NYSE: ABBV) and Amgen ... |
25,778 | 2018-01-05 00:00:00 UTC | Will J&J (JNJ) Continue to Tread Growth Path This Year? | ABBV | https://www.nasdaq.com/articles/will-jj-jnj-continue-to-tread-growth-path-this-year-2018-01-05 | null | null | Johnson & Johnson'sJNJ stock was up 21.3% in 2017, which compared favorably with a gain of 16.3% recorded by the industry .
What Drove the Stock in 2017?
Two new drugs were approved last year - Guselkumab/Tremfya in the United States as well as in the EU for plaque psoriasis and the first dual treatment for HIV, Juluca... | Please note that J&J markets Imbruvica in partnership with AbbVie, Inc. ABBV . Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To ... | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Please note that J&J markets Imbruvi... | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Please note that J&J markets Imbruvi... | Please note that J&J markets Imbruvica in partnership with AbbVie, Inc. ABBV . Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To ... |
25,779 | 2018-01-05 00:00:00 UTC | Key Biosimilar Approvals in 2017: Progress Report | ABBV | https://www.nasdaq.com/articles/key-biosimilar-approvals-in-2017%3A-progress-report-2018-01-05 | null | null | The biosimilar space was in focus in 2017 on key FDA approvals.
Biosimilars contain a version of the active substance of an already approved original biological drug. Development of biosimilars is technically more challenging than the development of generic drugs as the former requires clinical studies in patients and ... | Amgen's biosimilar version of Humir, Amjevita, is already approved by the FDA and will be launched in the United States on Jan 31, 2023, after the company resolved litigation with the AbbVie, Inc. ABBV The companies have also submitted a BLA to the FDA for ABP 980, a biosimilar candidate to Herceptin in July 2017. (AGN... | (AGN): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Amgen's biosimilar version of Humir, Amjevita,... | Amgen's biosimilar version of Humir, Amjevita, is already approved by the FDA and will be launched in the United States on Jan 31, 2023, after the company resolved litigation with the AbbVie, Inc. ABBV The companies have also submitted a BLA to the FDA for ABP 980, a biosimilar candidate to Herceptin in July 2017. (AGN... | Amgen's biosimilar version of Humir, Amjevita, is already approved by the FDA and will be launched in the United States on Jan 31, 2023, after the company resolved litigation with the AbbVie, Inc. ABBV The companies have also submitted a BLA to the FDA for ABP 980, a biosimilar candidate to Herceptin in July 2017. (AGN... |
25,780 | 2018-01-05 00:00:00 UTC | Biotech: The Tide Is Turning | ABBV | https://www.nasdaq.com/articles/biotech-tide-turning-2018-01-05 | null | null | By SA Marketplace :
2017 has been an exciting year in the markets. All-time highs seem to fall every week, the market has shaken off three Federal Reserve rate hikes as no big deal, and there is so much Bitcoin to talk about that it makes a head spin.
It's also been an exciting year on the Seeking Alpha Marketplace. Ma... | Neurocrine also has another potential blockbuster, elagolix, which it partnered with AbbVie ( ABBV ) and which should receive approval for endometriosis in 1H 2018 and report top-line results for uterine fibroids in the following weeks. I tend to focus on companies that are successfully homing in on niche opportunities... | Neurocrine also has another potential blockbuster, elagolix, which it partnered with AbbVie ( ABBV ) and which should receive approval for endometriosis in 1H 2018 and report top-line results for uterine fibroids in the following weeks. Our panel: Dr. Tran BioSci , author of Integrated BioSci Investing Terry Chrisomali... | Neurocrine also has another potential blockbuster, elagolix, which it partnered with AbbVie ( ABBV ) and which should receive approval for endometriosis in 1H 2018 and report top-line results for uterine fibroids in the following weeks. Our panel: Dr. Tran BioSci , author of Integrated BioSci Investing Terry Chrisomali... | Neurocrine also has another potential blockbuster, elagolix, which it partnered with AbbVie ( ABBV ) and which should receive approval for endometriosis in 1H 2018 and report top-line results for uterine fibroids in the following weeks. That is because there's a perception today that even if a drug gets approved, the c... |
25,781 | 2018-01-04 00:00:00 UTC | Can AbbVie (ABBV) Stock Keep the Momentum Alive in 2018? | ABBV | https://www.nasdaq.com/articles/can-abbvie-abbv-stock-keep-the-momentum-alive-in-2018-2018-01-04 | null | null | AbbVie Inc.ABBV shares are expected to be northbound in 2018, carrying on the momentum achieved last year. The stock was up 54.4% in 2017, comparing favorably with a gain of 16.3% recorded by the industry .
AbbVie carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks ... | Moreover, the agreement gave AbbVie ample time to focus on developing its pipeline and launching new products that will help make up for the loss of revenues once biosimilar Humira enters the market. AbbVie Inc.ABBV shares are expected to be northbound in 2018, carrying on the momentum achieved last year. AbbVie carrie... | AbbVie met primary endpoints in several pivotal studies - the key phase III MURANO study of Venclexta plus Roche's RHHBY Rituxan in relapse/refractory chronic lymphocytic leukemia; three phase III studies evaluating oral JAK-1 selective inhibitor, upadacitinib for rheumatoid arthritis and also a phase IIb study in atop... | AbbVie met primary endpoints in several pivotal studies - the key phase III MURANO study of Venclexta plus Roche's RHHBY Rituxan in relapse/refractory chronic lymphocytic leukemia; three phase III studies evaluating oral JAK-1 selective inhibitor, upadacitinib for rheumatoid arthritis and also a phase IIb study in atop... | AbbVie Inc.ABBV shares are expected to be northbound in 2018, carrying on the momentum achieved last year. AbbVie carries a Zacks Rank #2 (Buy). AbbVie met primary endpoints in several pivotal studies - the key phase III MURANO study of Venclexta plus Roche's RHHBY Rituxan in relapse/refractory chronic lymphocytic leuk... |
25,782 | 2018-01-04 00:00:00 UTC | ABBV Crosses Above Average Analyst Target | ABBV | https://www.nasdaq.com/articles/abbv-crosses-above-average-analyst-target-2018-01-04 | null | null | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $98.69, changing hands for $99.95/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a h... | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $98.69, changing hands for $99.95/share. But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions ... | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $98.69, changing hands for $99.95/share. But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions ... | There are 13 different analyst targets contributing to that average for AbbVie Inc, but the average is just that - a mathematical average. And so with ABBV crossing above that average target price of $98.69/share, investors in ABBV have been given a good signal to spend fresh time assessing the company and deciding for... | There are 13 different analyst targets contributing to that average for AbbVie Inc, but the average is just that - a mathematical average. In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $98.69, changing hands for $99.95/share. But the whole reason ... |
25,783 | 2018-01-04 00:00:00 UTC | 3 Large-Cap Pharma Stocks to Watch Out for This New Year | ABBV | https://www.nasdaq.com/articles/3-large-cap-pharma-stocks-to-watch-out-for-this-new-year-2018-01-04 | null | null | The year 2017 has turned out to be pretty impressive for the pharma/biotech stocks. Though the industry was hampered by drug pricing issues in 2016, it bounced back and made a considerable headway in 2017, courtesy of a slew of FDA approvals. The regulatory body approved 46 novel drugs last year, easily surpassing 2016... | AbbVie presented promising data from several pivotal studies, gained key regulatory approvals and settled its Humira patent disputes with Amgen AMGN . Below are the selected three companies, poised to continue their winning streak this year: AbbVie Inc.ABBV This Illinois-based biopharmaceutical company is a lucrative o... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Below are the selected three companies, poised ... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Below are the selected three companies, poised ... | Below are the selected three companies, poised to continue their winning streak this year: AbbVie Inc.ABBV This Illinois-based biopharmaceutical company is a lucrative option. AbbVie presented promising data from several pivotal studies, gained key regulatory approvals and settled its Humira patent disputes with Amgen ... |
25,784 | 2018-01-04 00:00:00 UTC | 18 Reasons I Like Biotech Stocks in 2018 | ABBV | https://www.nasdaq.com/articles/18-reasons-i-biotech-stocks-2018-2018-01-04 | null | null | Investing in biotech stocks comes with its own set of rules . Some people think biotech stocks are too risky. Not me. In my view, the potential for returns more than compensates for the risks -- with the right biotechs, at least.
I liked biotech stocks in 2017, and I still like them now that a new year has begun. Here ... | AbbVie (NYSE: ABBV) is on track to make $18 billion from top-selling Humira for 2017. Two that have already been mentioned, AbbVie and Gilead Sciences, pay excellent dividends. AbbVie's yield currently stands just under 3%, while Gilead's dividend yields only a little less at 2.9%. | *Stock Advisor returns as of January 2, 2018 Keith Speights owns shares of AbbVie, Celgene, Gilead Sciences, and SPDR S&P Biotech. AbbVie (NYSE: ABBV) is on track to make $18 billion from top-selling Humira for 2017. Two that have already been mentioned, AbbVie and Gilead Sciences, pay excellent dividends. | *Stock Advisor returns as of January 2, 2018 Keith Speights owns shares of AbbVie, Celgene, Gilead Sciences, and SPDR S&P Biotech. AbbVie (NYSE: ABBV) is on track to make $18 billion from top-selling Humira for 2017. Two that have already been mentioned, AbbVie and Gilead Sciences, pay excellent dividends. | AbbVie (NYSE: ABBV) is on track to make $18 billion from top-selling Humira for 2017. Two that have already been mentioned, AbbVie and Gilead Sciences, pay excellent dividends. AbbVie's yield currently stands just under 3%, while Gilead's dividend yields only a little less at 2.9%. |
25,785 | 2018-01-03 00:00:00 UTC | Biggest Blockbuster Drugs of All Time | ABBV | https://www.nasdaq.com/articles/biggest-blockbuster-drugs-all-time-2018-01-03 | null | null | A prescription drug that surpasses $1 billion in sales is known as a blockbuster. It's a rare feat, but when a pharmaceutical company finds a true blockbuster drug the payoff is enormous. How enormous? Check out the three best-selling prescription drugs of all time.
SEE ALSO: 15 All-Time Best-Selling Prescription Drugs... | Blockbuster Drug #2: Humira Company: AbbVie ( ABBV ) Treats: Ankylosing spondylitis, arthritis, Crohn's disease, plaque psoriasis, ulcerative colitis Lifetime sales: $109.2 billion Doctors praise Humira's ability to combat damaging inflammation caused by a number of diseases. Humira is owned by AbbVie, an industry gian... | Blockbuster Drug #2: Humira Company: AbbVie ( ABBV ) Treats: Ankylosing spondylitis, arthritis, Crohn's disease, plaque psoriasis, ulcerative colitis Lifetime sales: $109.2 billion Doctors praise Humira's ability to combat damaging inflammation caused by a number of diseases. Humira is owned by AbbVie, an industry gian... | Blockbuster Drug #2: Humira Company: AbbVie ( ABBV ) Treats: Ankylosing spondylitis, arthritis, Crohn's disease, plaque psoriasis, ulcerative colitis Lifetime sales: $109.2 billion Doctors praise Humira's ability to combat damaging inflammation caused by a number of diseases. Humira is owned by AbbVie, an industry gian... | Blockbuster Drug #2: Humira Company: AbbVie ( ABBV ) Treats: Ankylosing spondylitis, arthritis, Crohn's disease, plaque psoriasis, ulcerative colitis Lifetime sales: $109.2 billion Doctors praise Humira's ability to combat damaging inflammation caused by a number of diseases. Humira is owned by AbbVie, an industry gian... |
25,786 | 2018-01-03 00:00:00 UTC | Stocks With Rising Relative Price Strength: Grifols | ABBV | https://www.nasdaq.com/articles/stocks-rising-relative-price-strength-grifols-2018-01-03 | null | null | On Wednesday, Grifols ( GRFS ) hit an important technical milestone, with its Relative Strength ( RS ) Rating moving into the 80-plus percentile with an improvement to 82, up from 78 the day before.
[ibd-display-video id=2102289 width=50 float=left autostart=true] This unique rating identifies technical performance by ... | AbbVie ( ABBV ) is the No. On Wednesday, Grifols ( GRFS ) hit an important technical milestone, with its Relative Strength ( RS ) Rating moving into the 80-plus percentile with an improvement to 82, up from 78 the day before. Try This Simple Routine Grifols is trying to complete a cup without handle with a 24.30 buy po... | AbbVie ( ABBV ) is the No. Biotech And Pharmaceutical Industry And Stock News Stocks With Rising Relative Strength Ratings Why Should You Use IBD's Relative Strength Rating? How Relative Strength Line Can Help You Judge A Stock The views and opinions expressed herein are the views and opinions of the author and do not ... | AbbVie ( ABBV ) is the No. [ibd-display-video id=2102289 width=50 float=left autostart=true] This unique rating identifies technical performance by showing how a stock's price action over the last 52 weeks compares to that of other stocks on the major indexes. Biotech And Pharmaceutical Industry And Stock News Stocks W... | AbbVie ( ABBV ) is the No. [ibd-display-video id=2102289 width=50 float=left autostart=true] This unique rating identifies technical performance by showing how a stock's price action over the last 52 weeks compares to that of other stocks on the major indexes. Biotech And Pharmaceutical Industry And Stock News Stocks W... |
25,787 | 2018-01-02 00:00:00 UTC | 3 Best Big Pharma Stocks to Buy for 2018 | ABBV | https://www.nasdaq.com/articles/3-best-big-pharma-stocks-buy-2018-2018-01-02 | null | null | If you're expecting massive revenue growth for 2018 among big pharma stocks, think again. Despite hot new drugs for several major drugmakers, many of them also will likely be held back by declining sales for older drugs. Wall Street only expects low single-digit percentage revenue growth next year for most big pharma s... | Analysts expect more good news from the company this year: AbbVie is projected to generate revenue in 2018 of nearly $31 billion, a year-over-year increase of almost 11%. Here's why Johnson & Johnson (NYSE: JNJ) , AbbVie (NYSE: ABBV) , and Celgene (NASDAQ: CELG) appear to be the best big pharma stocks to buy for 2018. ... | Here's why Johnson & Johnson (NYSE: JNJ) , AbbVie (NYSE: ABBV) , and Celgene (NASDAQ: CELG) appear to be the best big pharma stocks to buy for 2018. AbbVie AbbVie posted its best year ever in 2017, with the stock soaring more than 54%. Analysts expect more good news from the company this year: AbbVie is projected to ge... | Here's why Johnson & Johnson (NYSE: JNJ) , AbbVie (NYSE: ABBV) , and Celgene (NASDAQ: CELG) appear to be the best big pharma stocks to buy for 2018. Celgene While AbbVie and Johnson & Johnson turned in impressive performances in 2017, Celgene stock dropped nearly 10% this year. AbbVie AbbVie posted its best year ever i... | Analysts expect more good news from the company this year: AbbVie is projected to generate revenue in 2018 of nearly $31 billion, a year-over-year increase of almost 11%. Here's why Johnson & Johnson (NYSE: JNJ) , AbbVie (NYSE: ABBV) , and Celgene (NASDAQ: CELG) appear to be the best big pharma stocks to buy for 2018. ... |
25,788 | 2018-01-02 00:00:00 UTC | Notable Tuesday Option Activity: FDX, WM, ABBV | ABBV | https://www.nasdaq.com/articles/notable-tuesday-option-activity-fdx-wm-abbv-2018-01-02 | null | null | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in FedEx Corp (Symbol: FDX), where a total volume of 13,428 contracts has been traded thus far today, a contract volume which is representative of approximately 1.3 million underlying shares (given that every 1... | Particularly high volume was seen for the $102 strike call option expiring January 19, 2018 , with 4,723 contracts trading so far today, representing approximately 472,300 underlying shares of ABBV. Below is a chart showing WM's trailing twelve month trading history, with the $87.50 strike highlighted in orange: And Ab... | Below is a chart showing WM's trailing twelve month trading history, with the $87.50 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 26,991 contracts, representing approximately 2.7 million underlying shares or approximately 63% of ABBV's average daily trading volume over the p... | Below is a chart showing WM's trailing twelve month trading history, with the $87.50 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 26,991 contracts, representing approximately 2.7 million underlying shares or approximately 63% of ABBV's average daily trading volume over the p... | Below is a chart showing WM's trailing twelve month trading history, with the $87.50 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 26,991 contracts, representing approximately 2.7 million underlying shares or approximately 63% of ABBV's average daily trading volume over the p... |
25,789 | 2017-12-29 00:00:00 UTC | AbbVie Inc Dividend at Risk Amid Patent Protection Problems | ABBV | https://www.nasdaq.com/articles/abbvie-inc-dividend-risk-amid-patent-protection-problems-2017-12-29 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie Inc (NYSE: ABBV ) is firing on all cylinders right now. ABBV stock is one of the Dividend Aristocrats, a group of 51 companies in the S&P 500 Index, with 25+ consecutive years of dividend increases.
AbbVie is one of 203 dividend stocks in the healthc... | AbbVie began trading as an independent company in 2013, after it was spun off from fellow pharmaceutical Dividend Aristocrat, Abbott Laboratories (NYSE: ABT ). Even with a relatively modest forecast of low-to-mid single digit revenue growth, there is a reasonable chance AbbVie's total annualized returns could reach dou... | Source: 2017 AbbVie Strategic Update , page 5 From 2013-2017, revenue and adjusted earnings-per-share rose for AbbVie stock at a compound annual rate of 11% and 16%, respectively, thanks in large part to the success of Humira. R&D expense in the past few years is below: 2014 research-and-development expense of $3.3 bil... | Source: 2017 AbbVie Strategic Update , page 5 From 2013-2017, revenue and adjusted earnings-per-share rose for AbbVie stock at a compound annual rate of 11% and 16%, respectively, thanks in large part to the success of Humira. Source: 2017 AbbVie Strategic Update , page 11 This is a significant risk for AbbVie, since H... | AbbVie expects Humira will still generate approximately $18 billion of revenue by 2020. Valuation & Expected Returns At the midpoint of AbbVie's earnings guidance for 2017, the stock is currently trading for a price-to-earnings ratio of 17. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE... |
25,790 | 2017-12-29 00:00:00 UTC | 4 Large-Cap Pharma Stocks That Outperformed the S&P This Year | ABBV | https://www.nasdaq.com/articles/4-large-cap-pharma-stocks-that-outperformed-the-sp-this-year-2017-12-29 | null | null | The pharma/biotech industry was plagued by drug pricing issues last year. However, it bounced back and made a considerable headway this year, courtesy of a slew of FDA approvals. Particularly, large-cap players in the industry raked in stellar returns, up 16.5%, not to forget that the same space posted a decline of 5.2... | AbbVie presented promising data from several pivotal studies, gained key regulatory approvals and settled its Humira patent disputes with Amgen. AbbVie Inc.ABBV This Illinois-based biopharmaceutical company also outperformed the S&P 500 so far this year. AbbVie's eight-week, pan-genotypic, ribavirin-free, once-daily HC... | Later in October too, AbbVie announced that three pivotal head-to-head phase III studies, evaluating risankizumab versus Johnson & Johnson's Stelara and Humira, for treatment of moderate-to-severe chronic plaque psoriasis, met all co-primary and secondary endpoints. Click to get this free report Roche Holding AG (RHHBY... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Astrazeneca PLC (AZN): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com cli... | AbbVie Inc.ABBV This Illinois-based biopharmaceutical company also outperformed the S&P 500 so far this year. AbbVie presented promising data from several pivotal studies, gained key regulatory approvals and settled its Humira patent disputes with Amgen. AbbVie's eight-week, pan-genotypic, ribavirin-free, once-daily HC... |
25,791 | 2017-12-27 00:00:00 UTC | Notable ETF Inflow Detected - VONE, DIS, ABBV, MCD | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-vone-dis-abbv-mcd-2017-12-27 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Russell 1000 ETF (Symbol: VONE) where we have detected an approximate $138.1 million dollar inflow -- that's a 17.7% increase week over week in outstanding units (from 6,350,000 to... | Among the largest underlying components of VONE, in trading today Walt Disney Co. (Symbol: DIS) is off about 0.3%, AbbVie Inc (Symbol: ABBV) is up about 0.1%, and McDonald's Corp (Symbol: MCD) is up by about 0.4%. For a complete list of holdings, visit the VONE Holdings page » The chart below shows the one year price p... | Among the largest underlying components of VONE, in trading today Walt Disney Co. (Symbol: DIS) is off about 0.3%, AbbVie Inc (Symbol: ABBV) is up about 0.1%, and McDonald's Corp (Symbol: MCD) is up by about 0.4%. For a complete list of holdings, visit the VONE Holdings page » The chart below shows the one year price p... | Among the largest underlying components of VONE, in trading today Walt Disney Co. (Symbol: DIS) is off about 0.3%, AbbVie Inc (Symbol: ABBV) is up about 0.1%, and McDonald's Corp (Symbol: MCD) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chann... | Among the largest underlying components of VONE, in trading today Walt Disney Co. (Symbol: DIS) is off about 0.3%, AbbVie Inc (Symbol: ABBV) is up about 0.1%, and McDonald's Corp (Symbol: MCD) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chann... |
25,792 | 2017-12-27 00:00:00 UTC | The 3 Best Dividend Aristocrats of 2017 | ABBV | https://www.nasdaq.com/articles/3-best-dividend-aristocrats-2017-2017-12-27 | null | null | The Dividend Aristocrats are components of the S&P 500 stock index that have each increased their dividend payments for at least 25 consecutive years. Like the overall stock market, the Dividend Aristocrats had a solid year in 2017 as a group, but there have been a few standout performers.
Here are the three highest-pe... | AbbVie had a few other notable wins this year, including strong performance from an experimental psoriasis drug and promising clinical trial results for a leukemia treatment. Note: AbbVie's dividend streak includes the years prior to its spinoff from Abbott Labs . AbbVie Unless something dramatic happens in the last fe... | Humira, AbbVie's key revenue generator, saw sales grow by 16% year over year, and further double-digit growth is expected by 2020. AbbVie had a few other notable wins this year, including strong performance from an experimental psoriasis drug and promising clinical trial results for a leukemia treatment. Note: AbbVie's... | Humira, AbbVie's key revenue generator, saw sales grow by 16% year over year, and further double-digit growth is expected by 2020. Note: AbbVie's dividend streak includes the years prior to its spinoff from Abbott Labs . AbbVie Unless something dramatic happens in the last few trading days of the year, AbbVie is the be... | AbbVie Unless something dramatic happens in the last few trading days of the year, AbbVie is the best-performing Dividend Aristocrat of 2017. Humira, AbbVie's key revenue generator, saw sales grow by 16% year over year, and further double-digit growth is expected by 2020. Note: AbbVie's dividend streak includes the yea... |
25,793 | 2017-12-27 00:00:00 UTC | Horizon Pharma Shows Improved Relative Price Performance; Still Shy Of Benchmark | ABBV | https://www.nasdaq.com/articles/horizon-pharma-shows-improved-relative-price-performance-still-shy-benchmark-2017-12-27 | null | null | Horizon Pharma ( HZNP ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Wednesday, with an upgrade from 69 to 76.
[ibd-display-video id=2385970 width=50 float=left autostart=true] This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. The grad... | AbbVie ( ABBV ) is the top-ranked stock within the group. Horizon Pharma ( HZNP ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Wednesday, with an upgrade from 69 to 76. [ibd-display-video id=2385970 width=50 float=left autostart=true] This exclusive rating from Investor's Business Daily measures ... | AbbVie ( ABBV ) is the top-ranked stock within the group. Horizon Pharma ( HZNP ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Wednesday, with an upgrade from 69 to 76. Biotech And Pharmaceutical Industry And Stock News IBD Stock Rating Upgrades: Rising Relative Strength Why Should You Use IBD's ... | AbbVie ( ABBV ) is the top-ranked stock within the group. While earnings growth fell in the company's most recently reported quarter from -27% to -63%, revenue grew 30%, up from 12% in the previous report. Biotech And Pharmaceutical Industry And Stock News IBD Stock Rating Upgrades: Rising Relative Strength Why Should ... | AbbVie ( ABBV ) is the top-ranked stock within the group. Horizon Pharma ( HZNP ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Wednesday, with an upgrade from 69 to 76. See if Horizon Pharma can continue to show renewed price strength and clear that threshold. |
25,794 | 2017-12-26 00:00:00 UTC | Health Care Sector Update for 12/26/2017: PTLA, ALXN, ABBV, ZSAN, RDY, NVS | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-12262017-ptla-alxn-abbv-zsan-rdy-nvs-2017-12-26 | null | null | Top Health care stocks:
JNJ: +0.6%
PFE: flat
ABT: flat
MRK: -0.1%
AMGN: flat
Health care shares were mixed in pre-market trading Tuesday.
Expected movers:
- Portola Pharmaceuticals ( PTLA ) said late Friday the US Food and Drug Administration will extend its review of the Biologics License Application (BLA) for AndexXa... | - Alexion Pharmaceuticals ( ALXN ) said the Ministry of Health, Labor and Welfare in Japan has approved Soliris (eculizumab) as a treatment for patients with generalized myasthenia gravis - AbbVie ( ABBV ) Friday prevailed when a US District Court judge overturned a $150 million jury verdict against the drug-maker due ... | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. - Alexion Pharmaceuticals ( ALXN ) said the Ministry of Health, Labor and Welfare in Japan has approved Soliris (eculizumab) as a treatment for patients with generalized myasthenia gravi... | - Alexion Pharmaceuticals ( ALXN ) said the Ministry of Health, Labor and Welfare in Japan has approved Soliris (eculizumab) as a treatment for patients with generalized myasthenia gravis - AbbVie ( ABBV ) Friday prevailed when a US District Court judge overturned a $150 million jury verdict against the drug-maker due ... | - Alexion Pharmaceuticals ( ALXN ) said the Ministry of Health, Labor and Welfare in Japan has approved Soliris (eculizumab) as a treatment for patients with generalized myasthenia gravis - AbbVie ( ABBV ) Friday prevailed when a US District Court judge overturned a $150 million jury verdict against the drug-maker due ... |
25,795 | 2017-12-26 00:00:00 UTC | Health Care Sector Update for 12/26/2017: LGND,IGC,INSY,ABBV | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-12262017-lgndigcinsyabbv-2017-12-26 | null | null | Top Health Care Stocks
JNJ -0.14%
PFE -0.04%
ABT +0.16%
MRK +0.01%
AMG -0.02%
Health care stocks were trading slightly higher today, including a 0.1% gain for the NYSE Health Care Index, while shares of health care companies in the S&P 500 were up almost 0.1% as a group. The Nasdaq Biotechnology Index was posting a 0.5... | + AbbVie ( ABBV ) has turned lower this afternoon, reversing an early advance following a U.S. District Court judge late last week overturning a $150 million jury verdict against the drugmaker following charges it had fraudulently misrepresented the risks of its AndroGel testosterone replacement drug. Among health care... | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. + AbbVie ( ABBV ) has turned lower this afternoon, reversing an early advance following a U.S. District Court judge late last week overturning a $150 million jury verdict against the dru... | + AbbVie ( ABBV ) has turned lower this afternoon, reversing an early advance following a U.S. District Court judge late last week overturning a $150 million jury verdict against the drugmaker following charges it had fraudulently misrepresented the risks of its AndroGel testosterone replacement drug. Health care stock... | + AbbVie ( ABBV ) has turned lower this afternoon, reversing an early advance following a U.S. District Court judge late last week overturning a $150 million jury verdict against the drugmaker following charges it had fraudulently misrepresented the risks of its AndroGel testosterone replacement drug. The Nasdaq Biotec... |
25,796 | 2017-12-23 00:00:00 UTC | Here's How AbbVie Inc. Crushed It in 2017 | ABBV | https://www.nasdaq.com/articles/heres-how-abbvie-inc-crushed-it-2017-2017-12-23 | null | null | It's been a tremendous year for AbbVie Inc. (NYSE: ABBV) shareholders. Shares of the Abbott spinoff have gained 56.5% this year as investors cheered a handful of important developments. As the year draws to a close, let's look back at a few ways AbbVie crushed it.
What biosimilar competition?
AbbVie investors can thank... | Image source: AbbVie Inc. Humira might be aging, but sales are as vibrant as ever, rising 16% on year in the third quarter to a stunning $18.8 billion annualized run rate. It's been a tremendous year for AbbVie Inc. (NYSE: ABBV) shareholders. As the year draws to a close, let's look back at a few ways AbbVie crushed it... | AbbVie Inc. CEO Richard Gonzalez gave investors plenty to smile about in 2017. AbbVie CEO Richard Gonzalez gave investors a lot to smile about in September when Amgen (NASDAQ: AMGN) agreed to license Humira intellectual property from AbbVie, beginning next year in the EU and not until 2023 in the vital U.S. market. It'... | AbbVie CEO Richard Gonzalez gave investors a lot to smile about in September when Amgen (NASDAQ: AMGN) agreed to license Humira intellectual property from AbbVie, beginning next year in the EU and not until 2023 in the vital U.S. market. Although I liked AbbVie much better at the beginning of the year when it was tradi... | It's been a tremendous year for AbbVie Inc. (NYSE: ABBV) shareholders. As the year draws to a close, let's look back at a few ways AbbVie crushed it. AbbVie investors can thank the company's legal team for the lion's share of this stock's gain in 2017. |
25,797 | 2017-12-22 00:00:00 UTC | Dividends & Income Digest: The Year In Review | ABBV | https://www.nasdaq.com/articles/dividends-income-digest-year-review-2017-12-22 | null | null | By Rebecca Corvino :
For our previous Dividends & Income Digest, I asked several authors about the year ahead and their 2018 watch lists. This time around, I'd like to take a step back and look at the year we're leaving behind, with a 2017 annual review.
Here's what several of our authors had to say about the past year... | By Rebecca Corvino : For our previous Dividends & Income Digest, I asked several authors about the year ahead and their 2018 watch lists. Adam Aloisi The Dividend Guy Julian Lin Stefan Redlich PendragonY Achilles Research Now, it's your turn to weigh in, in the comments below. Finally, here's some recent Dividends & In... | By Rebecca Corvino : For our previous Dividends & Income Digest, I asked several authors about the year ahead and their 2018 watch lists. Finally, here's some recent Dividends & Income content you might want to check out (if you haven't already): Dividend Growth 50: It's A Happy 3rd Anniversary, Even As Mr. Market Gets... | By Rebecca Corvino : For our previous Dividends & Income Digest, I asked several authors about the year ahead and their 2018 watch lists. I'd love to hear from you. Finally, here's some recent Dividends & Income content you might want to check out (if you haven't already): Dividend Growth 50: It's A Happy 3rd Anniversa... | By Rebecca Corvino : For our previous Dividends & Income Digest, I asked several authors about the year ahead and their 2018 watch lists. This time around, I'd like to take a step back and look at the year we're leaving behind, with a 2017 annual review. Finally, here's some recent Dividends & Income content you might ... |
25,798 | 2017-12-22 00:00:00 UTC | Better Stock: AbbVie (ABBV) vs. Eli Lilly (LLY) | ABBV | https://www.nasdaq.com/articles/better-stock-abbvie-abbv-vs-eli-lilly-lly-2017-12-22 | null | null | If AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) stocks were in a horse race in 2017, Lilly would have been ahead for most of the first half of the race. Over the summer, AbbVie would have pulled ahead by a nose. But by September, Lilly would have fallen well behind, with AbbVie kicking dust in its face. As the year dr... | AbbVie has the better growth prospects, in my view, with Humira and Imbruvica continuing to rock along and plenty of promising new drugs on the horizon. If AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) stocks were in a horse race in 2017, Lilly would have been ahead for most of the first half of the race. Over the summ... | If AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) stocks were in a horse race in 2017, Lilly would have been ahead for most of the first half of the race. Over the summer, AbbVie would have pulled ahead by a nose. But by September, Lilly would have fallen well behind, with AbbVie kicking dust in its face. | If AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) stocks were in a horse race in 2017, Lilly would have been ahead for most of the first half of the race. As the year draws to a close, AbbVie stock is up more than 55%, while Lilly stock is up close to 17%. The case for AbbVie AbbVie ranked as the best big pharma stock o... | If AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) stocks were in a horse race in 2017, Lilly would have been ahead for most of the first half of the race. Over the summer, AbbVie would have pulled ahead by a nose. But by September, Lilly would have fallen well behind, with AbbVie kicking dust in its face. |
25,799 | 2017-12-21 00:00:00 UTC | AbbVie's RA Candidate Meets Endpoints in 3rd Phase III Study | ABBV | https://www.nasdaq.com/articles/abbvies-ra-candidate-meets-endpoints-in-3rd-phase-iii-study-2017-12-21 | null | null | AbbVie Inc.ABBV announced that its investigational oral JAK-1 selective inhibitor, upadacitinib, met the primary endpoints in a phase III study from its SELECT program, which evaluated the candidate for the treatment of patients with rheumatoid arthritis ("RA").
AbbVie's shares have outperformed the industry so far thi... | AbbVie is also developing the candidate in psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and atopic dermatitis. Successful development of upadacitinib will boost AbbVie's RA portfolio, which already includes the blockbuster drug, Humira. AbbVie Inc.ABBV announced that its investigatio... | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Stock to Consider AbbVie carries a Zacks Rank #3 (Hold). Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report Celldex... | AbbVie Inc.ABBV announced that its investigational oral JAK-1 selective inhibitor, upadacitinib, met the primary endpoints in a phase III study from its SELECT program, which evaluated the candidate for the treatment of patients with rheumatoid arthritis ("RA"). AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Z... | AbbVie's shares have outperformed the industry so far this year. Successful development of upadacitinib will boost AbbVie's RA portfolio, which already includes the blockbuster drug, Humira. AbbVie Inc.ABBV announced that its investigational oral JAK-1 selective inhibitor, upadacitinib, met the primary endpoints in a p... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.